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“And if you find her poor, Ithaca has not deceived you. Wise as you have 
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Abstract 
 
Many enteric pathogens employ a type III secretion system to translocate effector 
proteins directly into the host cell cytoplasm, where they subvert signalling pathways of the 
intestinal epithelium. Once inside the cell, effector proteins may interact with host cell 
proteins to control various cellular processes. This enables enteric pathogens to establish 
their infective niche within the human host.  
The T3SS effectors EspO of enterohaemorrhagic Escherichia coli and Citrobacter 
rodentium, OspE of Shigella flexnerie and SopO of Salmonella enterica Serovar 
Typhimurium are known to interact with integrin-linked kinase to enhance cellular 
attachment to the substratum. In this project we demonstrate that the EspO family of 
effectors also interacts with the anti-apoptotic regulator Hax-1 and the co-chaperone 
DnaJB6.  
Employing fluorescence microscopy we found that ectopically expressed EspO 
resides on large cytosolic vacuoles, which stained positive for the endoplasmic reticulum 
marker CREB3. Moreover, ectopic expression of EspO changed the cellular distribution of 
endogenous Hax-1, which co-localized with the EspO vacuoles. We found that the EspO 
orthologs are anti apoptotic, protecting cells from apoptosis triggered by multiple inducers 
including staurosporine (a global kinase inhibitor), tunicamycin (induces unfolded protein 
response) and thapsigargin (interferes with Ca2+ homeostasis). Additionally, EspO protects 
HeLa cells from the apoptosis induced in EPEC infections. Hax-1 depleted HeLa cells by 
siRNA showed that the anti apoptotic activity of the EspO orthologs is Hax-1 dependent. 
 6 
Using the C. rodentium in-vivo model of EHEC / EPEC infections, we found that 
deletion of espO results in decreased levels of hyperplasia similar to the uninfected control. 
The mutant strain also showed low levels of neutrophils and CD4+T cells, whereas the 
EspO complemented strain showed a dramatic increase in both inflammatory cells. These 
results suggest new mechanisms unique to the T3SS EspO family of effectors, which might 
shed new insights regarding the infection strategies followed by enteric pathogens. These 
results suggest new mechanisms unique to the T3SS EspO family of effectors, which might 
shed new insights regarding the infection strategies followed by enteric pathogens.  
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1 Chapter 1 : Introduction 
 
1.1 Enteric Bacterial Pathogens 
 
Enteric bacteria comprise a group within the gamma Proteobacteria and share similar 
phenotypic characteristics with its members mainly being natural inhabitants of the 
intestinal tract of humans and animals. They are described as gram-negative, non-
sporulating rods that can be motile or non-motile with peritrichous (uniformly distributed 
around the body) flagella. Escherichia, Salmonella and Shigella are closely related enteric 
bacteria (Figure 1) and the pathogenic strains within each genus have evolved many 
strategies to survive within an infected host and avoid the defence mechanisms to establish 
an efficient colonisation of the intestinal epithelium leading to specific disease outcomes.  
Enteropathogenic E. coli (EPEC) was the first E. coli strain linked to human disease. 
Although, it is currently prevalent mainly in developing countries as a major cause of 
infantile diarrheal diseases, recent data may suggest its re-emergence in the UK [1]. EPEC 
outbreaks are often associated with high mortality rates, which range between 10% and 
40%. Humans are considered the main host and outbreaks usually occur as a cause of close 
contact between children [1]. However, animals (e.g. dogs, cattle) may also act as EPEC 
reservoirs [2, 3]. The closely related enterohaemorrhagic E. coli (EHEC) are foodborne 
pathogens that cause diarrhoea, haemorrhagic colitis and the potentially lethal haemolytic 
uraemic syndrome - HUS [4]. Production of Shiga-like toxins (Stx) presents HUS, which is 
the leading cause of acute paediatric renal failure in the UK and USA. Approximately 1 in 
every 10 EHEC (particularly serotype O157) cases reported each year in the UK would be 
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HUS in children under 16. In adults, a complication similar to HUS may occur, which is 
known as thrombotic thrombocytopenic purpura (TTP) affecting the blood but the brain and 
nervous system can also be affected. Epidemiological data published by the Health 
Protection Agency (HPA) show 1182 E. coli O157 cases reported in England and Wales for 
2011[http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/EscherichiaColiO157/
EpidemiologicalData/].  
 
Figure 1. Targeting the intestine (Designed by author) 
Diagram shows the relationship between enteropathogenic E. coli (EPEC) that infects the 
small intestine and presents the major cause of infantile diarrheal diseases in developing 
countries with its main host being humans and animals; enterohaemorrhagic E. coli (EHEC) 
with main reservoir being the cattle and similarly to Shigella, infects the large intestine with 
the disease outcomes ranging from diarrhea to hemolytic uremic syndrome (HUS) and Non-
typhoidal Salmonella enterica (e.g. S. Typhimurium), which are food-borne pathogens that 
cause self-limiting gastroenteritis with diarrhea or S. Typhi that cause a systemic disease 
with high fever and headache. Diagram designed by the author for this study.  
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The genus Salmonella contains only the two species, Salmonella enterica and 
Salmonella bongori, according to the classification provided by the Centre of Disease 
Control (CDC) [CDC Salmonella annual surveillance report summary: Available at 
http://www.cdc.gov/ncidod/dbmd/phlisdata/salmonella.htm]. S. enterica further subdivides 
into six subspecies and based on the human clinical syndromes, these are limited to only two 
types of strains. These types are described as typhoidal or not depending on the specific 
infecting strain. Salmonella enterica, which is also a foodborne pathogen, is considered a 
significant burden in industrialised and under-developed countries [5, 6]. Non-typhoidal 
Salmonella enterica (NTS) is the cause of self-limiting gastroenteritis and is estimated to 
cause 1 billion cases (93.8 million cases leading to 155,000 deaths per year according to 
World Health Organisation – WHO) of foodborne gastroenteritis annually [5]. More 
recently, multiple antibiotic-resistant strains have emerged as important cause of fatal 
invasive bacteraemia, particularly in sub-Saharan regions [7, 8]. In epidemiological data 
provided by HPA for England and Wales, 2000-2010 indicate S. Typhimurium (1959 cases 
in 2010) and S. Enteritidis (2444 cases in 2010) the most infectious Salmonella strains 
[http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Salmonella/Epidemiologic
alData/salmDataHuman/]. 
Shigella is a genus comprised of four species and these are subdivided into several 
serotypes. S. sonnei, which is the only Shigella species with just one serotype is more 
prevalent in developed countries whereas S. flexneri and S. dysenteriae are more common in 
developing countries. Shigellosis remains a global endemic disease responsible for 165 
million cases of severe dysentery and 1 million deaths annually, particularly in children less 
than five years of age. Only in year 2002, the epidemiological data provided by WHO 
indicate an estimate of 4.5 billion diarrhoeal cases with 1.8 million deaths 
[http://www.who.int/topics/global_burden_of_disease/en/]. In addition, more than half a 
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million cases of shigellosis are reported among travellers and military personnel. HUS has 
been described as a complication of Shigella infections and it can be mild with easy 
recovery but it may also have the more severe outcome, which results in fatal kidney failure 
[WHO – Guidelines for the control of Shigella epidemics: WHO/CDR/95.4, 
http://www.who.int/csr/en/]. 
Similar strategies of infection are followed by enteric pathogens, which employ a 
type III secretion system (T3SS) to deliver bacterial proteins, known as effectors, into the 
cytosol of the mammalian host cell. These effectors hijack and subvert various host cell 
processes, including the function of Rho GTPases, actin dynamics, protein ubiquitination, 
phagocytosis, apoptosis and inflammatory signalling, which enable the pathogen to 
colonise, multiply, cause disease and spread within the infected host. Unlike EPEC or 
EHEC, Shigella and Salmonella sp. use their T3SS to invade gut epithelial cells.  
Intracellular Shigella gains entry into the basolateral side of the intestinal epithelium 
by M cell transcytosis (Microfold or M cells are included in the group of epithelial cells and 
their specialty is the cellular mechanism of vesicular transport of molecules from one side of 
the cell to the other or from the gut lumen to the underlying mucosa) [9-11]. After release 
from M cells, Shigella is engulfed by macrophages where it resides within the phagosome 
very briefly and then escapes, induces cell death and eventually released into the basolateral 
side [12-14]. Using the T3SS encoded on the Mxi-Spa locus, the pathogen promotes uptake 
by the intestinal epithelium and soon after engulfment, Shigella escapes the phagosome to 
spread from cell to cell laterally with the aid of actin based-motility (Figure 2) [15-17]. The 
escape from the phagosomes also enables the replication of the intracellular organism within 
the infected host cell [18]. On the contrary, Salmonella invades the intestinal epithelium 
from the apical surface using the T3SS-1 harboured in Salmonella pathogenicity island 1 
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(SPI-1). The pathogen resides within the phagosome (Salmonella containing vacuole - SCV) 
where the SPI-2 T3SS mediates intracellular survival and replication (Figure 2).  
EPEC and EHEC colonise the intestinal mucosa, while remaining extracellular, 
through formation of attaching and effacing (A/E) lesions (Figure 2). These lesions are 
induced following an interaction between the T3SS effector Tir and the outer membrane 
adhesin intimin, both of which are encoded on the LEE pathogenicity island. The focus of 
this project are the T3SS effector orthologs EspO of EHEC O157:H7, which contains two 
espO paralogs, and the A/E mouse pathogen C. rodentium, which encodes one copy of 
espO, OspE of Shigella flexneri and SopO Salmonella enterica serovar Typhimurium. 
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Figure 2. Life cycle of enteric bacteria (Designed by author) 
EPEC and EHEC utilise their T3SS to form attaching and effacing lesions shown by the rise 
of pedestal-like structures on which the bacteria rest to establish their infective niche while 
remaining extracellular. Shigella and Salmonella invade the intestinal epithelium using their 
T3SS and further maintain an intracellular life cycle. Details of the host cell signalling 
processes and T3SS effectors involved in pathogenesis are explained later. Illustration was 
designed by the author for this study.  
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1.2 Pathogenic Escherichia coli  
 
Firstly described by Theodor Escherich in 1885 as Gram-negative rod-shaped 
bacteria, Escherichia coli (E. coli) is now classified in the family Enterobacteriaceae of the 
gamma-proteobacteria. As the predominant aerobic bacterial commensal of the 
gastrointestinal tract of humans and other mammals, E. coli can coexist with its host without 
any disease onset [19]. However a number of E. coli clones have acquired virulence 
abilities, which enable them to cause a wide spectrum of human diseases such as diarrhoea, 
urinary tract infections, sepsis or meningitis.  
Diarrhoeagenic E. coli have been traditionally divided into 6 pathotypes (Figure 3). 
The Enteropathogenic E. coli (EPEC) that targets the small bowel epithelium and along with 
Enterohaemorrhagic E. coli (EHEC), which is distinguished by the Stx production and 
targets the colon, introduced the family of A/E pathogens. Enterotoxigenic E. coli (ETEC) 
targets the small bowel and secretes enterotoxins, whereas Enteroaggregative E. coli 
(EAEC) commonly adheres to both small and large bowel forming biofilms and secreting 
enterotoxins and cytotoxins. Enteroinvasive E. coli (EIEC) similar to Shigella sp. enters the 
epithelium within a vacuole and moves intracellularly by actin-based motility. Diffusely 
adherent E. coli (DAEC) also acts in the small bowel but induces cellular projections of the 
microvilli to enclose the bacteria. Recently, another two pathotypes have emerged; Adherent 
Invasive E.coli (AIEC) and the Shiga Toxin producing Enteroaggregative E.coli (STEAEC), 
which was the main cause of the recent outbreak in Europe, 2011 [Published by WHO at  
http://www.euro.who.int/__data/assets/pdf_file/0009/144981/EHEC_outbreak_10_June_20
11.pdf.] 
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Figure 3. Traditional Diarrhoeagenic E.coli pathotypes.  [19] 
Illustration of the six pathotypes included in the diarrhoeagenic E. coli. (a) The 
Enteropathogenic E. coli (EPEC) encoding the bundle-forming pilus [BFP] (a.2) forms 
microcolonies (a.1) and it is included in the A/E pathogens (a.3) along with 
Enterohaemorrhagic E. coli (EHEC) shown in (b) and Enteroinvasive E. coli (EIEC) shown 
in (e) to form attaching and effacing lesions described by the rise of pedestal-like structures 
on which the bacteria rest and a functional T3SS is required for the A/E lesions. 
Diarrhoeagenic E. coli also include Enterotoxigenic E. coli (ETEC) shown in (c), 
Enteroaggregative E. coli (EAEC) shown in (d) and Diffusely adherent E. coli (DAEC) 
shown in (f), which are included in the pathotypes that are non-T3SS dependent. 
 
Pathogenic strains are differentiated according to specific clinical disease caused, 
virulence factors and serotypic analysis, which is dependent on the O (somatic) and H 
(flagellar) antigens. In terms of virulence factors, pathotypes are also divided into T3SS 
dependent (EHEC, EPEC and EIEC) and non-T3SS dependent (ETEC, EAEC, STEAEC, 
DEAC and AIEC). A serotype with an emergent medical, as well as scientific, importance is 
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O157:H7 due to its ability to cause fatal outbreaks of foodborne disease worldwide. E. coli 
O157 is a member of EHEC which is regarded as a zoonotic pathogen with the main 
reservoir being cattle and other ruminants [20]. Transmission to humans is mediated through 
the consumption of contaminated food e.g. undercooked meat, milk, fruit and vegetables 
[21, 22]. Moreover, a human-to-human transmission is possible via the faecal-oral route due 
to the low infective dose (<100 colony-forming units) [23]. 
EHEC infections can lead to either non-bloody or bloody diarrhoea, haemorrhagic 
colitis or haemolytic uremic syndrome [4] with the latter being the most serious 
complication leading to acute renal failure in children. EHEC strains belong to the larger 
group of pathogenic clones known as Shiga toxin (Stx) producing E.coli (STEC). Most of 
the EHEC specific symptoms are directly linked to the production of Stx, also known as 
verocytotoxin. In EHEC, the different Stx variants are all encoded on a bacteriophage [19, 
24]. The toxin is released in the colon and induces damages of the intestinal epithelial cells 
leading to bloody diarrhoea. Upon successful entry into the bloodstream the toxin is 
transported to the kidney where it destroys the renal endothelial cells leading to HUS.  
Although O157:H7 is the most common and virulent serotype implicated worldwide 
in human disease, non-O157 EHEC serotypes (O26, O103, O111, O118 and O145) are also 
prevalent. Based on certain phenotypic differences, EHEC is divided into two divergent 
clones EHEC 1 (Figure 4.a) which includes O157:H7 and O55:H7 (atypical EPEC 
considered to be the ancestor of O157:H7) and EHEC 2, which includes mainly the non-
O157 EHEC serotypes (Figure 4.b).  
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Figure 4. Evolutionary divergence of EPEC and EHEC pathotypes. [25] 
Diagram showing evolutionary steps in the divergence of EPEC and EHEC pathotypes. The 
diagrams depict the presence of the LEE at two different loci; selC shown in (a) and pheU 
shown in (b). EHEC is divided into two divergent clones EHEC 1 (3.a) that includes 
O157:H7 and O55:H7 (atypical EPEC considered to be the ancestor of O157:H7) and 
EHEC 2 that includes mainly the non-O157 EHEC serotypes (3.b). EPEC strains are divided 
in lineage 1 (3.a) that are characterised by the expression of the flagellar antigen H6 and O 
serogroups include O55, O119, O125, O127 and O142. EPEC strains in lineage 2 express 
the H2 antigen and O serogroups O111, O114, O126 and O128 (3.b). EPEC strains are 
further divided into typical EPEC (tEPEC) harbouring the EAF plasmid, which encodes the 
bundle-forming pilus or atypical EPEC (aEPEC) lacking the EAF plasmid. 
 
EPEC strains, frequently described as the cause of infantile diarrhoea in the 
developing world, are divided into two evolutionally distinct lineages (Figure 4). EPEC 
strains belonging in lineage 1 (Figure 4.a) are characterised by the expression of the 
flagellar antigen H6 and O serogroups include O55, O119, O125, O127 and O142. Those in 
lineage 2 express the H2 antigen and O serogroups include O111, O114, O126 and O128 
(Figure 4.b). Additionally, EPEC strains are divided into typical EPEC (tEPEC) to describe 
strains harbouring the EAF plasmid, which encodes the bundle-forming pilus or atypical 
EPEC (aEPEC) lacking the EAF plasmid. Typical EPEC consists mainly of the serogroups 
O55, O86, O111, O119, O127 and O142 and atypical EPEC includes an even broader 
spectrum of O serogroups.  
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1.3 Attaching and Effacing Pathogens 
 
Following bacterial colonisation of the gut mucosa, the so-called attaching / effacing 
(A/E) lesions are formed on the apical surfaces of enterocytes (Figure 5). These 
characteristic lesions describe the effacement of microvilli and the rise of pedestal-like 
structures on which the bacteria rest (Figure 1). The ability to form these lesions is 
dependent on the LEE (locus of enterocyte effacement) pathogenicity island, which encodes 
a type III secretion system (T3SS), effector proteins (Tir, Map, EspF, EspG, EspH and 
EspZ), gene regulators, intimin, chaperones and translocators (Figure 5) [26]. The A/E 
pathogen family includes EHEC, EPEC and the mouse-specific pathogen Citrobacter 
rodentium all of which share the LEE pathogenicity island and various effector proteins 
[27].  
 
Figure 5. Attaching / Effacing (A/E) lesions in EPEC. [28] 
The effacement of microvilli and the rise of pedestal-like structures on which the bacteria 
rest shown in A. (Scanning Electron Micrograph) and B. (Transmission Electron 
Micrograph).  The genome organisation of LEE (locus of enterocyte effacement) 
pathogenicity island depicted in C. 
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The outer membrane adhesin, was the first gene product shown to be essential for 
this intimate attachement of bacteria [29]. Intimin is encoded by the eae gene located within 
the LEE and following secretion, the adhesin is inserted into the bacterial outer membrane 
[30]. The A/E pathogens also maintain a gene coding for an intimin-specific receptor. Tir or 
transmembrane intimin receptor is a LEE-encoded effector translocated via the T3SS into 
the host cell and targeted to the plasma membrane to interact with intimin and hence, allow 
the intimate bacterial attachment with the host cell [31, 32]. In addition to Tir, intimin can 
also interact with nucleolin, a host cell protein shown to be up-regulated in the presence of 
Stx [33].  
Various studies have shown that different EPEC and EHEC strains encode distinct 
intimin and Tir types. To date, 27 intimin and 8 Tir types have been reported.  Differences 
in the antigenicity of intimins is related to host tissue tropism. For example, the intimin 
expressed by EHEC O157:H7 has shown tropism towards the human and cattle follicle-
associated epithelium [34, 35]. The one expressed by EPEC O127:H7 shows more 
specificity to the epithelium lining the small intestine and less specificity towards the large 
intestine, whereas the intimin from EHEC O103:H- shows low adherence levels in both 
small and large intestine [36, 37].  
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1.4 Type III secretion system 
Gram-negative pathogens are able to interfere with biochemical pathways of their 
target cells via a complex multiprotein apparatus known as type III secretion system (T3SS), 
which is used to export effector proteins by directly delivering them into the host cell 
cytosol, a process known as translocation [38, 39]. Although, at the molecular level the 
T3SS between enteric pathogens slightly varies, the general consensus comprises of a 
cytosolic ATPase, the inner and outer membrane rings connected by the periplasmic 
channel, the projection channel required for protein export and the extracellular needle-like 
structure or injectisome. Approximately 20 genes encode the structural components of the 
T3SS. 
 
 
 
 
 
 
 
 
Figure 6. The type III secretion apparatus of EHEC / EPEC. [26] 
The illustration depicts the type III secretion apparatus of EHEC and EPEC, which is 
encoded by genes located on the LEE pathogenicity island. It is comprised of the cytosolic 
ATPase, the inner (EscR, S, T, U, V) and outer (EscC) membrane rings connected by the 
periplasmic channel (EscJ), the projection channel (EscF) required for protein export and 
the extracellular needle-like structure or injectisome (EspA). The translocator proteins EspB 
and EspD form the membrane translocation pore that allows entry into the host cell 
cytoplasm. 
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In EHEC / EPEC the T3SS is comprised of protein rings which span the outer 
(EscC) and inner (EscR, S, T, U, V) membranes, EscJ which links the two membrane rings 
through a periplasmic channel and EscF that forms the projection channel required for 
protein secretion (Figure 6) [26]. In addition, a filamentous extension is generated by the 
polymerization of the translocator EspA [40]. Effector proteins travel through the EspA 
filament to reach a membrane translocation pore, formed by the translocator proteins EspB 
and EspD, which allow the entry into the cytoplasm [41].  
The set of genes that encode the T3SS are found on plasmids or pathogenicity 
islands (PAI). In EHEC or EPEC the T3SS genes are located on the LEE PAI, 
S.Typhimurium has two PAIs called SPI-1 and SPI-2 that harbour the genes encoding for 
the T3SS and S. flexneri contains the T3SS genes within a plasmid. It is thought that 
horizontal gene transfer events have resulted in the acquisition of the T3SS to many gram-
negative bacteria [42]. Despite the fact that all these enteric pathogens share a similar T3SS 
at the molecular level, there are significant differences in their interactions with host cells 
and this is mainly due to the diversity in effector repertoires.  
There are seven distinct families of T3SS and the S. Typhimurium SPI-1 encoded 
T3SS along with the S. flexneri T3SS are the main examples of the second family. The 
T3SS in EHEC, EPEC and S. Typhimurium SPI-2 encoded T3SS are included in the third 
family [38]. This could be directly related to their pathogenesis where EHEC / EPEC remain 
extracellular and Salmonella or Shigella have an intracellular life cycle.  
Their entry into epithelial cells but also their intracellular fate differs. For example 
Salmonellae utilize their SPI-1 T3SS to enter through the apical surface and remain 
enclosed within the SCV where the SPI-2 T3SS maintains survival and replication within 
the infected host. In contrast, Shigellae employ their T3SS to invade the epithelium and then 
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rapidly lyse the vacuole to enter the cytoplasm for replication and actin-based lateral spread 
into neighbouring cells [18, 43, 44]. However, EHEC / EPEC utilise their T3SS while being 
extracellular to translocate effector proteins and further establish an infective niche.  
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1.5 T3SS Effector Proteins 
 
The translocation of T3SS effector proteins initiates the “biochemical cross-talk” 
between bacterial pathogens and their target cells [45]. This results in the subversion of 
various host cell processes, including the function of Rho GTPases, actin dynamics, 
phagocytosis, apoptosis and inflammatory signalling. In EHEC, the LEE codes for six 
effector proteins (Map, Tir, EspG, EspF, EspH and EspZ) [26] and at least 62 (including 12 
pseudogenes) effector genes are estimated to exist around the chromosome [27, 46]. The 
diversity of effector protein repertoire within the A/E pathogens has been shown by various 
genome projects. The EPEC strain E2348/69 encodes 21 effectors and the incomplete 
genome sequences of EPEC strains E22 and E110019 encode at least 40 and 24 effectors 
respectively. In addition, the mouse specific A/E pathogen, C. rodentium encodes 30 
effectors. A total of 21 effector proteins, also known as core effectors, are conserved among 
EHEC, EPEC and C. rodentium [46]. 
The non-LEE encoded effectors were described when the complete genome 
sequencing of EHEC O157:H7 has led to the identification of specific loci, named 
exchangeable effector loci (EELs) which contain most of the genes whose products are 
predicted or already known to be effectors [47]. The EELs were further divided into three 
groups; the pathogenicity islands (LEE and SpLE3), the lamboid prophages that contain 
most of the effector proteins and non-phage EELs. Examples of non-LEE encoded effectors 
include NleH whose gene is located on lamboid prophage Sp9 and acts as an inhibitor of 
apoptosis and subverts NFκB [48]; EspJ which is involved in phagocytosis and its gene is 
found on prophage Sp14 [49]; NleE whose gene is located on SpLE3 pathogenicity island is 
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known to block the nuclear translocation of p65 subunit of NF-κB leading to the 
manipulation of the host inflammatory pathway [50].  
 
1.5.1 Interacting with host cells 
 
The initial step towards an established infection, bacterial pathogens adhere or 
invade host cells through an intimate interaction. The cytoskeleton of the host cell is directly 
affected from these interactions and it is targeted mainly due to its important role in 
maintaining a normal cell physiology like cell architecture and selective epithelial 
permeability, transport and phagocytosis. Enteric bacterial pathogens like EPEC, EHEC, C. 
rodentium, S. Typhimurium and S. flexneri whose virulence is dependent to a great extent 
on the T3SS, inject numerous effector proteins to subvert the host cell cytoskeleton.  
In EPEC, EHEC or C. rodentium the LEE-encoded effector Tir, which is inserted 
into the host cell plasma membrane acts as the receptor for the bacterial outer membrane 
protein, intimin (Figure 7) [31]. This interaction leads to the activation of cellular proteins 
N-WASP and the Arp2/3 complex leading to actin polymerisation which is responsible for 
the pedestal formation beneath the attached bacteria [51, 52]. In EPEC infections, the 
recruitment of N-WASP requires an interaction of Tir and the adaptor protein Nck [53]. 
This interaction is initiated by the phosphorylation of Tir at tyrosine 474 (Y474p) [54, 55]. 
On the contrary, EHEC promotes a different process of actin polymerisation due to its Tir 
lacking a tyrosine 474 equivalent (Figure 7). The T3SS effector protein, TccP (Tir-
cytoskeleton coupling protein), also known as EspFu interacts with the proteins IRSp53 and 
IRTKS, which also bind Tir and thus, providing an indirect link of TccP/EspFu with Tir [56, 
57]. This promotes an interaction of TccP/EspFu with N-WASP leading to its activation by 
 30 
preventing its autoinhibition fold and hence, initiating an Nck-independent actin 
polymerisation pathway [58]. 
In contrast to EPEC and EHEC, Salmonella and Shigella subvert the cytoskeleton by 
targeting signalling pathways that lead to actin membrane ruffles, which enclose the 
infecting bacterium and allow the intiation of its intracellular life cycle. In Salmonella, the 
T3SS located on SPI-1 pathogenicity island is used for invasion into the intestinal epithelial 
cells. The SPI-1 encoded effectors, which are initially translocated into the infected cell to 
promote the internalisation of Salmonella include SipA [59] and SipC [60] that stabilise 
actin, SopE or SopE2 that induce membrane ruffles and lamellipodia through Rho-GTPase 
activation [61], SptP that counteracts the action of SopE and the phosphatidylinositol 
phosphatase SopB that also modulates invasion by indirect activation of Cdc42 Rho-GTPase 
[62-64]. Interestingly, SipA stimulates the early activation of caspase-3, which in turn 
cleaves the effector at a specific recognition motif that leads to two independent functional 
SipA domains [65]. In S. Typhimurium, this process appears to be common for many T3SS 
effector proteins (e.g. SopA, SopB, SopD, SopE, SptP and SifA) but potential caspase-3 
recognition sequences are also predicted to exist in effector proteins from other enteric 
bacteria (Section 1.7 includes related information on the EspO family of effectors).  
Inside the SCV (Salmonella-containing vacuole), the bacteria utilise the T3SS 
harboured in SPI-2 for intracellular survival and replication. The SPI-2 encoded effector, 
SifA promotes formation of the Salmonella-induced filaments (Sifs), which protrude from 
the SCV and elongate along the microtubules [66, 67] (Figure 7). This is suggested to be a 
Salmonella-specific mechanism used to fascilitate the interaction of SCV with other vesicles 
and further maintain the integrity of the vacuole [67, 68]. 
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However, Shigella enters the intestinal epithelial cells through the basolateral side of 
the intestinal epithelium (Figure 7). The pathogen moves through M cells by transcytosis 
and upon release, Shigella is taken by macrophages where it can replicate and cause cell 
death [69]. When macrophages die, the bacteria are released in the submucosa and access 
the basolateral site of the epithelium. Host cell adhesion of Shigella is mediated by the 
interaction of the T3SS translocator proteins with two receptors. The translocator IpaB binds 
CD44 and the complex IpaBCD binds integrin α5β1, which result in lipid rafts accumulating 
at the site of bacterial entry [70, 71].  
Similar to Salmonella, Shigella also induces actin membrane ruffles that enclose the 
bacteria and promote invasion. The process of internalisation followed by escape from 
phagolysosome is mediated by the action of T3SS effectors like the bacterial Rho GTPases 
IpaC [72], IpgB1 and IpgB2 [73-75], IpaA that promotes actin depolymerisation [75], the 
EPEC/EHEC EspG homolog, VirA that destabilises microtubules [76] and the IpaB [77] 
and IpaH(7.8) [78] that allow the phagosomal escape. Additionally, the inositol 4-
phosphatase IpgD dephosphorylates phosphatidylinositol-4,5-biphosphate and this results in 
membrane and actin remodelling [79].  
After lysis of the phagosome, Shigella establishes its replicative niche within the 
cytosol and further spreads laterally to neighbouring cells through actin-based motility. The 
recruitment of the T3SS effector VirG (also known as IcsA or intracellular spread A) at one 
pole of the bacterial cell allows directed motility within the cytoplasm of the infected cell 
[15, 80]. VirG attracts and further activates the actin polymerisation proteins, N-WASP and 
ARP 2/3 [81-83]. However, VirG is also targeted by the autophagy protein 5 (ATG5) and its 
integrity as well as inhibition of autophagy is maintained by the effector IcsB [84]. 
Additionally, the intracellular movement and lateral spread of Shigella requires VirA to 
degrade α-tubulin and further destabilise the microtubule network [85].  
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Figure 7. Bacterial interactions with host cell (Designed by author) 
EPEC / EHEC T3SS effector Tir binds intimin to initiate actin polymerisation leading to 
pedestal formation. In EPEC phosphorylation of Tir initiates the interaction with Nck 
adaptor that recruits N-WASP and ARP 2/3, whereas EHEC Tir recruits the IRTKS/IRSp53 
proteins, which interact with the T3SS effector TccP/EspFu that activates N-WASP. 
Salmonella SPI-1 T3SS effectors SopE, SopE2, SopB, SptP, SipA and SipC are all essential 
for internalisation. The integrity of the Salmonella-containing vacuole (SCV) is fascilitated 
by the SPI-2 T3SS effector SifA. Shigella translocators IpaB and the complex IpaBCD are 
required for host cell receptor binding. The effectors IpgB, VirA, IpaA and IpgD mediate 
Shigella invasion. The Shigella effector VirG is protected by IcsB that inhibits autophagy 
and allows VirG to recruit N-WASP and ARP 2/3 for actin-based movement. The Shigella 
VirA, which is the EPEC/EHEC EspG homolog disrupts the microtubule network and 
promotes intracellular movement and lateral spread of Shigella. Illustration designed by the 
author for this study. 
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In addition, T3SS effectors that are known to disrupt the Rho GTPase signalling and 
therefore, modulate the actin dynamics are also found in EPEC or EHEC [86] (Figure 8). 
The Rho family of small G proteins involved in the regulation of crucial cellular functions 
include Cdc42, Rac1 and RhoA, which induce filopodia, lamellipodia/ruffles and stress 
fibers respectively [87]. Bacterial effector proteins involved in the Rho GTPase signalling 
were grouped in the WxxxE family based on a conserved motif of two amino acids Trp and 
Glu separated by three variable amino acids [74]. The family comprises members from 
EPEC/EHEC e.g. Map, EspM, EspT, from Shigella spp e.g. IpgB1, IpgB2, IpaC and VirA 
and from Salmonella spp e.g. SopE, SopE2, SopB, SptP and SifA [63, 72, 74, 76, 86].  
The T3SS effectors can function as guanine exchange factors (GEFs), which control 
the switch from the inactive GDP-bound to the active GTP-bound state, or GTPase-
activating proteins (GAPs), which control the hydrolysis of GTP to revert back to the 
inactive state [88, 89]. Map and EspM function as GEFs on Cdc42 and RhoA respectively 
and EspT activates both Rac1 and Cdc42 [90-92]. Subversion of actin dynamics was also 
shown with the T3SS effector EspH which affects filopodia and pedestal formation by 
inactivating the mammalian only Rho GEFs, suggesting an EspH-dependent clearance of 
eukaryotic GEFs allowing the bacterial GEFs / WxxxE effectors to modulate the Rho 
GTPase signalling [93, 94]. Interestingly, a large number of the WxxxE repertoire is 
involved in the disruption of tight junctions and intestinal barrier [86]. Examples from 
EPEC or EHEC include Map and EspF from the WxxxE family (but also EspI) and the 
Salmonella SopB, SopE, SopE2 and SipA may additionally disrupt the tight junctions  
(Figure 8) [26, 95, 96].  
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Figure 8. Modulating the actin dynamics (Designed by author) 
Examples of T3SS effectors in EPEC / EHEC (Map, EspT, EspM and EspH), Salmonella 
(SopE, SopB and SptP) and Shigella spp. (IpgB and IpaC) that subvert the small G-protein 
signalling by direct activation or deactivation of the Rho GTPase family members Rac1 that 
induces membrane ruffles or lamellipodia, Cdc42 that promotes filopodia formation and 
RhoA that induces stress fibers. In addition to other effectors, many of the Rho GTPase 
signalling modulators may also dirsupt the tight junctions or intestinal barrier function. 
Illustration was designed by the author for this study. 
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1.5.2 Pass-through host cell defence  
 
Apart from the intimate interactions with the intestinal epithelila cells, the T3SS is 
also necessary for avoiding the immune system. When bacterial pathogens enter the 
intestinal epithelium, the host cell pattern recognition is triggered via pattern recognition 
receptors (PRRs) and the innate or adaptive host cell immune response is activated. The 
PRRs include the Toll-like receptor family (TLR) and the Nod-like receptor family, which 
can specifically sense the pathogen-associated molecular patterns (PAMPs). These are 
pathogen-related motifs that involve the bacterial flagella and lipopolysaccharides. Once the 
PAMPs are recognised, the PRRs can activate the immune signalling responses leading to 
the phosphorylation and degradation of the inhibitory IκB proteins allowing the release of 
the bound dimeric transcription factor NF-κB [97, 98]. This is followed by the translocation 
of NF-κB to the nucleus and hence, initiation of transcription that is specific to 
inflammatory response (Figure 9).  
Successful colonization leading to an established EHEC / EPEC infection requires 
amongst other factors, the bacterial manipulation of the host immune response and 
inhibition of phagocytosis. The NF-κB nuclear translocation is blocked by the effector 
proteins NleE and NleB (Figure 9), which inhibit the IκB degradation [50, 99]. The 
metalloproteases NleC and NleD can prohibit inflammatory responses by either targeting 
NF-κB or the mitogen activated protein kinases c-Jun N-terminal Kinase (JNK) and p38 
respectively [100, 101]. In addition, previous work on the NleH effectors has shown both an 
upregulation of inflammatory responses but also an attenuation of NF-κB activation [102, 
103]. NleH1 blocks the nuclear translocation of the RPS3 subunit of NF-κB whereas NleH2 
induces expression of RPS3 coding genes [103-105]. The balance of pro- and anti- 
inflammatory responses is further maintained by the action of the multifunctional effector 
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EspT, which in addition to its role in actin polymerisation it can also induce the expression 
of pro-inflammatory genes through Erk, JNK and NF-κB pathways [106]. 
Similar to EHEC / EPEC, examples of T3SS effectors involved in the manipulation 
of immune responses also exist in other enteric pathogens such as Shigella and Salmonella. 
The Shigella effector OspF and the Salmonella homologue, SpvC block MAP kinase 
phosphorylation and down-regulate the expression of a subset of NF-κB-dependent genes 
[107-109]. OspZ, the NleE homologue from Shigella, shares the same NF-κB inhibitory 
activity [50]. The EHEC / EPEC NleH effectors are homologous to the Shigella OspG, 
which inhibits degradation of IκB and therefore, blocks activation of NF-κB [102, 110].  
The IpaH9.8 from Shigella and the SspH1 from Salmonella act as E3 ubiquitin ligases and 
affect the inflammatory MAPK signalling [111, 112]. Additionally, the Shigella effectors 
OspB and OspF were shown to cause particular chromatin remodelling that dampens the 
levels of IL-8 production [113]. Furthermore, the activity of SspH1 in Salmonella is 
balanced by the SPI-2 T3SS effector SseL, which acts as a deubiquitinase [114]. In 
Salmonella, the T3SS located on SPI-2 is also required for the systemic spread of the 
infection via infected phagocytes that is regulated by the SPI-2 T3SS effector, SrfH/SseI 
[115]. 
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Figure 9. Manipulation of host cell defence (Designed by author) 
Receptors sense bacterial infection and activate the downstream inflammatory signalling 
pathways. EPEC or EHEC effectors NleE, NleB, NleH and Shigella effector OspG inhibit 
the degradation of IκB and hence, suppress the nuclear translocation of NF-κB dimers p50 
and p63. EPEC / EHEC effector, NleD targets JNK and p38 to suppress activation of AP-1, 
ATF-2 and c-Jun transcription factors. NleC (EPEC / EHEC), IpaH9.8, OspF and OspB 
(Shigella) and SspH1 (Salmonella) are targeted to the nucleus and affect cytokine 
transcription levels. Host cell defence is also avoided through direct inhibition of immune 
cells; EPEC / EHEC effectors EspB, EspF, EspJ and EspH suppress phagocytosis and IpaB 
from Shigella or SipB from Salmonella induce cell death in macrophages through activation 
of the inflammatory caspase-1, which results in the activation and release of the 
proinflammatory cytokines IL-18 and IL-1β. Illustration was designed by the author for this 
study. 
 
 38 
EHEC / EPEC have also evolved mechanisms to inhibit phagocytosis and therefore, 
maintain their extracellular life cycle. Internalisation of both unopsonised (cis-phagocytosis) 
and opsonised (trans-phagocytosis) bacteria, is inhibited by the effector EspF (Figure 9), 
which inhibits PI3K activation [116]. EspB can interact with several members of the myosin 
superfamily and hence, inhibit cis-phagocytosis whereas EspJ has been shown to inhibit 
trans-phagocytosis [117, 118]. Additionally, the effector EspH, which was previously shown 
to inactivate the Rho GTPase signalling, can also inhibit both cis- and trans- phagocytosis 
[94].  
Both Salmonella and Shigella utilise mechanisms that allow survival within the 
phagosome and therefore, maintain their intracellular cycle. For example, Salmonella can 
survive within the macrophages by suppressing the phagocytic process in a SPI-2 T3SS 
fashion [119, 120]. In Shigella, the T3SS effector VirG that is essential for the intracellular 
actin-based motility, may also induce autophagy. This is suppressed by the action of another 
T3SS effector, IcsB that protects VirG from the cellular autophagy protein 5 (ATG5) and 
therefore, promote intracellular survival (Figure 7) [84]. In addition, the S.Typhimurium 
SipB translocated by the SPI-1 T3SS is known to induce a rapid onset of apoptosis through 
binding and activating the pro-apoptotic caspase-1 (Figure 9) [114, 121]. This apoptotic 
mechanism is also shared by the effector IpaB, the SipB homologue in Shigella [122, 123]. 
Activation of caspase-1 results in the cleavage of pro-IL-1β and pro-IL-18 that generates 
their active forms and their subsequent release from the dying macrophage [124, 125].  
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1.5.3 Fighting for survival 
 
 
An established infective niche within the host is further maintained by balancing 
pro- and anti- apoptotic effectors to modulate apoptosis. Also known as programmed cell 
death, it describes the tightly regulated form of cell death that is mediated by specialised 
proteases named caspases, which regulate all three pathways (Discussed in detail later). It 
has been shown that apoptotic pathways are initiated in EHEC / EPEC infection and they 
can be triggered by either bacterial surface properties or the translocation of effector 
proteins [126, 127]. Known effector proteins involved in the induction of apoptosis include 
the effectors, EspF and Cycle inhibitory factor (Cif) (Figure 10). EspF is targeted to the 
mitochondria to interfere with the mitochondrial membrane potential, which induces the 
release of cytochrome c and cleavage of caspases -9 and -3 [128]. Cif has been shown to 
function as a bacterial cyclomodulin subverting the eukaryotic cell cycle resulting in 
apoptosis [129].  
The action of pro-apoptotic effectors in EHEC / EPEC is balanced with the NleH 
family effectors, which block apoptosis via an interaction with the anti-apoptotic protein, 
Bax Inhibitor-1 [48]. The effector NleD also has an anti-apoptotic function by inactivating 
JNK, which results in the suppression of the transcription factor AP-1 involved in the 
regulation of apoptosis, proliferation and inflammation [101]. In addition, the EPEC or 
EHEC EspO family of effectors that includes OspE from Shigella and SopO from 
Salmonella bind integrin linked kinase (ILK) to promote the cell attachment to the 
submucosa and hence, maintain cell survival [130] (Figure 10). Similarly, the effector EspZ 
binds CD98, a host protein involved in integrin mediated cell adhesion and survival [131].   
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Figure 10. Balancing apoptosis (Designed by author) 
Activation of apoptotic pathways by EPEC or EHEC effectors EspF (disruption of 
mitochondrial membrane potential) and Cif (cell cycle arrest) is balanced by the anti-
apoptotic effector NleH that binds Bax-inhibitor 1 (BI-1). The EspO family of effectors that 
includes EspO from EPEC/EHEC, OspE from Shigella and SopO from Salmonella maintain 
cell survival through enhanced cell attachment. Illustration was designed by the author for 
this study. 
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As previously mentioned both Salmonella and Shigella are able to induce caspase-1 
dependent apoptosis in macrophages [132, 133]. Salmonella was shown to induce apoptotic 
death in either SPI-1 or SPI-2 manner [134]. The SPI-1 T3SS effector SipB is involved in 
the caspase-1 dependent cell death, which is an early onset of apoptosis during the course of 
infection but interestingly, it can also induce a delayed apoptotic event that is caspase-1 
independent [121, 135-137]. After prolonged infection, Salmonella may additionally utilise 
the SPI-2 T3SS to induce apoptosis in a caspase-1 dependent fashion in macrophages or via 
caspase-3 activation in epithelial cells [138-140]. The Salmonella SipB homolog in Shigella 
is IpaB and shares the same apoptotic function that mediates cell death through caspase-1 
activation in macrophages [123, 141].  
      These apoptotic events are balanced by the SPI-1 T3SS effector SopB from 
Salmonella and its homolog IpgD from Shigella, which activate the phosphatidylinositol 3-
kinase (PI3K)/Akt pathway [142, 143]. Akt is an anti-apoptotic protein that inhibits the 
release of cytochrome-c from mitochondria and therefore, prevents the activation of 
caspases [144]. Furthermore, the Shigella induced apoptosis in epithelial cells is inhibited by 
genes regulated by MxiE, the transcriptional activator of genes encoding a second wave of 
effectors that are secreted via the T3SS machinery intracellularly [145-147]. Intriguingly, 
the transcription of ospE (the espO homologue in Shigella) is under the control of MxiE 
[148].  
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1.6 Citrobacter rodentium: In-vivo model of infection   
 
Citrobacter rodentium was firstly found in the mid-1960s from sporadic murine 
diarrhoeal outbreaks [149-151]. At the time, it was designated as an atypical Citrobacter 
freundii strain as the causative agent of one of these outbreaks and classified as atypical 
murine pathogenic E. coli (MPEC) for another [149, 150]. However, it was later shown that 
in all cases diarrhoea was accompanied by epithelial cell hyperproliferation or hyperplasia 
in the descending colon and in addition, their DNA relatedness has led to the classification 
of all C. freundii and MPEC isolates as C. rodentium species [152, 153].  
The infectious disease is now known as transmissible murine colonic hyperplasia 
(TMCH) and describes pathological changes such as thickening of the colon, intestinal 
epithelial crypt elongation and goblet cell loss [153, 154]. Colonic tissue extracted from 
infected mice has shown intimate attachment of the bacteria to the epithelial cell surface 
with localised destruction of the brush-border microvilli, reminiscent of the A/E lesions in 
EPEC and EHEC infections [153]. As previously discussed, the A/E lesion formation is 
essential for pathogenicity and the genes responsible for induction of these lesions are 
harboured in the LEE pathogenicity island (Reviewed in Section 1.3). Therefore, due to its 
natural virulence in mice and the inability of EPEC / EHEC to infect mice, C. rodentium 
acts as an ideal in-vivo animal model for infection. 
The roles of both LEE and non-LEE effectors and virulence genes in TMCH have 
been studied extensively in C. rodentium. Absence of the T3SS intimin receptor, Tir has 
shown attenuated C. rodentium colonization and virulence in mice [155, 156]. Map, which 
is known to interfere with the mitochondrial function, disrupt the intestinal barrier and 
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induce formation of filopodia shows no significant changes in colonization and disease 
when absent [157, 158]. Infection with an EspF (involved in mitochondrial membrane 
permeabilisation and disruption of the intestinal barrier) mutant indicated a moderate 
attenuation, whereas EspG (involved in microtubule network disruption) is not essential for 
pathogenesis in-vivo [158]. In addition, non-LEE effectors, which are not required for A/E 
lesion formation, still exhibit a significant role in infection as shown in competitive studies 
of C. rodentium mixed infections of wild-type and mutant strains. EspI/NleA mutant is 
rapidly outcompeted by the wt strain and mice infected with an EspJ mutant took longer to 
clear [49, 157].  
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1.7 Programmed Cell Death: Apoptosis 
 
1.7.1 Cell Death: An Overview 
 
Cell death was firstly identified in 1858 but knowledge within the field has mainly 
increased only in the past 40 years [159]. Historically, different terms of the cell death 
concept have been introduced to describe the three major morphologically distinct pathways 
of cell death (Figure 11); by the genetic mechanism named apoptosis or Type I programmed 
cell death; by lysosomes, which mainly describe the Type II programmed cell death or 
autophagy but also involved in necrosis and apoptosis; and by physicochemical stress e.g. 
heat shock or free radicals leading to necrosis [159]. Although, cell death may occur through 
a variety of biochemically distinct pathways, they are all interconnected to provide a 
fundamental cellular response that plays an important role in animal development and tissue 
homeostasis [159, 160]. 
Within the last 20 years, the mechanisms underlying cell death have been limited to 
the programmed or tightly regulated form of cell death as opposed to the more unordered or 
accidental form [159]. Ischemic cell death or oncosis, which describes the failure of ionic 
pumps in the plasma membrane, is considered to be the only accidental form of cell death 
[159, 161]. Although, necrosis has been improperly coined as a term to describe accidental 
cell death, it is now considered as a regulated process that includes the secondary changes 
resulting from any cell death mechanism [160, 161].  The main feature of accidental cell 
death is swelling, which led to the name oncosis (derived from the Greek onkos, meaning 
swelling) [159]. Oncosis leads to necrosis with cellular swelling, membrane blebbing and 
karyolysis (dissolution of the cell nucleus) as opposed to apoptosis, which leads to necrosis 
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with cell shrinkage, chromatin condensation (pyknosis) and karyorhexis (nuclear 
fragmentation) [159-161].   
 
Figure 11. An overview of the major pathways of cell death. [162] 
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1.7.2 Programmed Cell Death 
 
Programmed cell death Type I or apoptosis is the best-characterised type of 
regulated cell suicide and describes the typical morphological features of apoptotic cells, 
which eventually break down into apoptotic bodies and removed by phagocytes [163-165]. 
Apoptosis in Greek is used to denote “falling off” to describe leaves falling off a tree. The 
scientific term apoptosis describes the regulated physiological process of removing 
individual components of an organism without damaging the organism. Three tightly 
controlled pathways are known to result in apoptosis, which involve biochemical events 
leading to the activation of proteases known as caspases (cysteine-dependent aspartate-
specific proteases).  Autophagy or programmed cell death Type II describes the degradation 
of cellular components by autophagic vacuoles and is featured by partial chromatin 
condensation and vacuolisation. Autophagosomes are the primary vesicles to engulf 
cytoplasmic material, which then fuse with lysosomes to proceed with the degradation. Cells 
undergoing autophagy are then phagocytised by neighbouring cells.  
However, apart from apoptosis and autophagy, other types of programmed cell death 
have been characterised and the specific mechanism determining cell fate depends mainly 
upon the initiating stimulus [163].  Pyroptosis is another form of regulated cell death, which 
was firstly seen in Salmonella and Shigella infections (Figure 11) [162, 163]. The name is 
derived from the Greek “pyro” meaning fire or fever and “ptosis” meaning falling off and 
pyroptosis is used to denote proinflammatory cell death. Similarly to apoptosis, one of the 
caspases, known as caspase-1 was shown to mediate pyroptosis but not apoptosis. 
Additionally, pyronecrosis is another form of regulated cell death, which was firstly seen in 
Shigella infections [166]. The term was coined to describe a form of necrotic cell death that 
may lead to the activation of caspases through initiation of a cathepsin-dependent apoptotic 
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mechanism. Cathepsins are proteases, which are localised within lysosomes under 
physiologic conditions and released in response to certain stress signals to induce normal 
apoptotic cell death [167].  
A mechanism previously seen to show features of both apoptosis and necrosis was 
named necroptosis [168, 169]. Although, similar apoptotic stimuli induce necroptosis, the 
main mediator is a kinase with death-domain, known as RIP1, which is activated upon Fas 
ligand-induced and tumor necrosis factor-α (TNF-α) induced necroptosis. Various inhibitors 
specific to this mechanism have been identified and they were all classified in the family of 
necrostatins according to their ability to inhibit the kinase activity of RIP1 [170]. 
Additionally, necrosis can be induced in response to DNA damage, which leads to the 
activation of the DNA repair protein, poly(ADP-ribose) polymerase (PARP) [171, 172]. The 
cells respond with an increased energy consumption to support the activation of PARP and 
this leads to depletion of ATP, which triggers cell death [173].  
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1.7.3 Apoptosis: Pathways determining Cell Suicide 
 
This tightly regulated form of cell death whose role is very crucial in various human 
diseases like cancer, autoimmune diseases and neurodegenerative diseases has led to an 
increased interest to identify the genes involved in the initiation, execution and regulation of 
apoptosis. The conserved family of caspases is central for a successful apoptotic cell 
response and maintains an irreversible biochemical cascade leading to cell suicide [174]. 
Caspases were firstly identified in a developmental processes study in Caenorhabditis 
elegans model and homologues were then shown to exist in all mammals. The main feature 
of caspases includes their proteolytic activity, which leads to the cleavage of proteins at 
aspartic acid residues. According to their role in apoptosis, caspases were further 
categorized into initiators (caspase-2, -8, -9 and -10), executioners (caspase-3, -6 and -7) 
and inflammatory caspases (caspase-1, -4 and -5) [175]. In addition, caspases-11, -12, -13 
and -14 have been identified but their role has not been fully characterized [165].    
Although, for many years it was thought that only two main pathways were involved 
in apoptosis, there is now evidence that a third pathway also exists. Named according to the 
specific apoptotic stimuli inducing each pathway, they are known as the intrinsic, extrinsic 
and perforin / granzyme pathways [165]. However, they are all interconnected and converge 
on the same downstream execution pathway (Figure 12). This shared pathway involves the 
cleavage and hence, activation of caspase-3, the main executioner of apoptosis, which leads 
to DNA fragmentation, degradation of numerous proteins, formation of apoptotic bodies, 
ligands for phagocytic cell receptors and ends with the uptake by phagocytic cells.  
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1.7.3.1 Intrinsic Pathway 
The intrinsic pathway leading to apoptosis is initiated by numerous non-receptor 
mediated stimuli, which activate mitochondrial-initiated events. Such stimuli can either act 
in a positive manner i.e. toxins, radiation, hypoxia or viral infections or negatively in the 
absence of certain cytokines, hormones and growth factors involved in the suppression of 
apoptosis [165]. In both types, the mitochondrial permeability transition (MPT) pore opens 
to change the mitochondrial transmembrane potential leading to the release of pro-apoptotic 
proteins in the cytosol (Figure 12).  
Early events include the release of cytochrome c, Smac/DIABLO and HtrA2/Omi to 
activate the caspase-dependent pathway [164, 176]. In the cytosol, cytochrome c directly 
interacts with Apaf-1 and pro-caspase-9 to form a trimeric complex known as the 
apoptosome [177]. This conformation activates caspase-9, which in turn cleaves and 
activates caspase-3. In contrast, Smac/DIABLO and HtrA2/Omi act by suppressing the 
regulation of caspases via direct inactivation of the inhibitors of apoptosis (IAPs) [178]. One 
such inhibitor, X-linked IAP or XIAP is able to block the proteolytic activity of caspases 
through direct binding and either Smac or HtrA2 can inhibit its action [176]. As a late event, 
pro-apoptotic proteins like the apoptosis-inducing factor (AIF), caspase-activated DNase 
(CAD) and endonuclease G are released from the mitochondria [171]. This event essentially 
leads to chromatin condensation and DNA fragmentation either in a caspase –dependent 
(CAD) or –independent (AIF and endonuclease G) manner.   
These apoptotic events are tightly regulated by a total of 25 proteins included in the 
Bcl-2 family, which is further controlled by the tumor suppressor protein p53 [179]. Bcl-2 
family members are divided in two groups, the anti-apoptotic (Bcl -2, -x, -XL, -XS, -w, 
BAG) and the pro-apoptotic (Bcl-10, Bax, Bak, Bid, Bad, Bim, Bik, Blk) proteins [179-
181]. Whether a cell commits suicide or aborts the death program is determined by the 
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action of Bcl-2 proteins. Although, information regarding individual Bcl-2 members exists, 
further elucidation is required for an in-depth understanding of the crucial steps leading to 
the execution phase of apoptosis.  
1.7.3.2 Extrinsic Pathway 
The extrinsic pathway is governed by extracellular death signals induced by 
interactions with transmembrane receptors included in the tumor necrosis factor (TNF) 
receptor family [182]. They all share similar extracellular and cytoplasmic domains, which 
are required for successful initiation of the intracellular signalling pathways of apoptosis 
(Figure 12).  Although, the known members of the family with their ligands include 
FasR/FasL, TNFR1/TNF-a, DR3/Apo3L, DR4/Apo2L and DR5/Apo2L, only the specific 
mechanisms followed by Fas and TNF-a are currently fully understood [182, 183].   
In both mechanisms, the cytoplasmic adapter protein FADD is recruited to transmit 
the intracellular signals via association with pro-caspase-8. The resulting complex known as 
DISC (death-inducing signalling complex) promotes the auto-activation of caspase-8, which 
in turn triggers the execution phase. The only known negative mechanism to regulate the 
extrinsic pathway involves the protein c-FLIP, which can bind both FADD and caspase-8 to 
inhibit the DISC formation.    
1.7.3.3 Perforin / Granzyme Pathway 
The Fas mechanism of the extrinsic pathway leading to apoptosis is a form of T-cell 
mediated cytotoxicity, which is mediated by cytotoxic T lymphocytes (CTLs) to kill tumor 
and virally infected cells [165, 182]. In addition to Fas, CTLs can also mediate another 
pathway that involves the transmembrane pore-forming protein known as perforin (Figure 
12). Granules containing proteases are then secreted through the perforin-formed pore and 
into the cytosol of the target cell.  
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The proteases granzyme A and B are crucial in CTL-induced apoptosis which 
involves both caspase dependent and independent downstream pathways (Figure 12). 
Granzyme B can directly activate caspases -3 and -10 but can also cleave and in this case 
suppress the action of ICAD (Inhibitor of Caspase Activated DNAse). Additionally, 
granzyme B has been implicated in the release of cytochrome c through cleavage of Bid, a 
pro-apoptotic Bcl-2 family member. Activation of Bid is an example of “cross-talk” 
between all three main pathways of apoptosis. On the contrary, granzyme A induces a 
caspase independent pathway through activation of the DNAse NM23-H1 leading to DNA 
degradation.  
1.7.3.4 Execution Pathway 
Once the cell has been irreversibly committed to suicide, the shared execution 
pathway is initiated. The main executioner is caspase-3 but caspases -6 and -7 are also 
involved in this phase of apoptosis [165]. Activation of such executioner caspases leads to 
chromatin condensation, nuclear fragmentation and cytoskeletal protein degradation, which 
all contribute to the morphological changes of apoptotic cells [164]. The cytoskeletal re-
organisation is followed by the decomposition of the cell into membrane-enclosed 
fragments, known as apoptotic bodies. Recognition by phagocytic cells is facilitated by the 
externalisation of phosphatidylserine on the surface of apoptotic cells.  
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Figure 12. Programmed Cell Death Pathways. (Reviewed in [164]) 
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1.7.4 Calcium-induced Apoptosis 
 
Survival through changing environments is maintained by the cellular 
communication governed by calcium (Ca2+) and phosphate ions. Amazingly, Ca2+ is one of 
the simplest ions known and yet controls everything in the life of Homo sapiens; from birth 
to death [184, 185]. Movement, heart beat, information processing by the brain and storage 
of memories are only a few of the activities regulated by Ca2+ as an intracellular messenger. 
It further coordinates cellular development and differentiation into specialised types, 
controls their activity and triggers their death.  
Concentrations of Ca2+ within the cytosol determine cell fate. In high concentrations 
cells will disintegrate following either the necrotic or apoptotic cell death pathways [186]. In 
normal Ca2+ signalling, the ER and mitochondria communicate via constant shuttling of the 
ion to maintain higher levels in the ER lumen where Ca2+ resides and less in the 
mitochondria [187]. When this homeostatic cross talk between the two organelles changes, 
Ca2+ acts as an orchestrator of apoptosis [188]. The ER Ca2+ stores are depleted, leading in 
an overloading of mitochondrial Ca2+ and the combination of these has the consequence of 
either trigger stress signals that activate genes associated with cell death or initiate the 
downstream programmed events of mitochondria-induced apoptosis.  
The Ca2+ concentrations within the cell cytosol are altered either via an external or 
internal source. It can enter the cell through plasma membrane spun Ca2+ channels, pumps 
or exchangers when neighbouring cells activate signalling [189]. Intracellularly the main 
source of Ca2+ is the ER but many other organelles also require the ionic messenger for 
normal functioning. Although, different types of transporters associated with various 
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organelles have been identified to date, in many cell types the ER localised transporters are 
those directly implicated in the induction or amplification of apoptotic signals [189, 190].  
The sarcoendoplasmic reticulum Ca2+ ATPase (SERCA) pumps import Ca2+ ions 
from the cytoplasm and ER release of Ca2+ is regulated by inositol triphosphate (IP3) and 
ryanodine receptors [190]. When these ER-specific regulators are impaired, Ca2+ 
homeostasis is altered leading to cell death (Figure 13). Additionally, members of the Bcl-2 
family, derived from both the pro- and anti- apoptotic groups are involved in the regulation 
of ER Ca2+ load since the balance between the anti-apoptotic Bcl-2 (decreases ER Ca2+ load) 
and the pro-apoptotic proteins Bax and Bak (increase mitochondria Ca2+ load) is directly 
proportional to Ca2+ homeostasis [191, 192].  
 
Figure 13. Calcium homeostasis in programmed cell death. [193] 
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1.7.5 The Apoptotic Regulator HAX-1 
 
HS-1-associated-protein-X-1 (Hax-1) was discovered more than a decade ago in a 
yeast two-hybrid screen and since then its binding partner repertoire has been on a constant 
increase [194, 195]. Due to its numerous interactions, Hax-1 is involved in many cellular 
pathways [196]. However, growing evidence highlights its role in apoptosis as the main 
function (Figure 14). It has been implicated in diseases that involve diminished progression 
of apoptosis e.g. cancer and severe congenital neutropenia and considered a ubiquitously 
expressed protein interacting with multiple anti-apoptotic proteins [195, 196].  
The intracellular stability of XIAP is dependent on a direct interaction with Hax-1, 
which prevents proteosomal degradation of XIAP and thus, promotes its anti-apoptotic 
function (Figure 14) [197]. Overexpression of Hax-1 also results in resistance to pro-
apoptotic events signaled by granzyme B and caspase-3 as well as inhibition of caspase-9 
[198-200]. Although, its intracellular localization has taken an atypical distribution pattern 
the consensus HeLa cell localization includes the mitochondria, ER and nuclear membrane 
[196]. This depicts an intracellular distribution of Hax-1 that involves organelles regulating 
different pathways of programmed cell death. Indeed, apart from the intrinsic and granzyme 
pathways, Hax-1 also regulates apoptosis through modulation of Ca2+ homeostasis [195].  
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Figure 14. Hax-1 regulates apoptosis (Designed by author) 
Hax-1 protects one of the main inhibitors of apoptosis (XIAP) from degradation. The 
interaction of caspase-9 with Hax-1 inhibits the apoptosome formation and the main 
executioner of apoptosis, caspase-3. Inhibition of apoptosis induced by ER stress is 
maintained by the interaction of Hax-1 with the ER Ca2+  importer pump SERCA2 and the 
ER Ca2+ efflux channel PKD2. During apoptosis, Hax-1 degradation is fascilitated by direct 
caspase-3 and HtrA2/Omi cleavage. The role of the Hax-1 nuclear localisation has not been 
identified yet. Illustration was designed by the author for this study. 
 
Hax-1 participation in Ca2+ homeostasis was firstly coined through its interaction 
with the ER localised polycystic kidney disease type II, PKD2 or TRPP2 [201]. In a dimeric 
complex, PKD1 and PKD2 form cationic channels that permit a two-way direction Ca2+ flux 
[202]. The PKD2 channels were shown to inhibit apoptosis by permitting less ER Ca2+ 
export to the cytosol and mitochondria in association with the ER Ca2+ efflux channels, 
inositol triphosphate receptors (IP3Rs) [203, 204]. It was later shown that Hax-1 related 
contribution to Ca2+ homeostasis also involves an interaction with the SERCA2 pumps, 
which play a crucial role in the regulation of Ca2+ levels by maintaining the interplay 
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between the ER and mitochondria [205]. Previous work has shown that Hax-1 C-terminus 
binds the nucleotide-binding domain of SERCA2 to prevent specific conformational 
rearrangements normally occurring via ATP hydrolysis. Evidence suggests that 
overexpression of Hax-1 results in down-regulation of SERCA2, which leads to inhibition 
of apoptosis through diminished ER Ca2+ content allowing normal mitochondrial Ca2+ load 
[205]. This Hax-1 inhibitory mechanism is consistent with the action of Bcl-2, another anti-
apoptotic regulator known to promote cell survival by reducing ER Ca2+ efflux [192].  
Regulation of Hax-1 expression levels is maintained by the pro-apoptotic 
Omi/HtrA2 and caspase-3 which were both shown to cleave and hence, deactivate Hax-1 
during apoptosis [199, 206]. Furthermore, evidence suggests that hax-1 transcription is 
regulated by NF-κB [207]. Importantly, many viruses (e.g. human immunodefficiency, 
Epstein-Barr and classical swine fever viruses) target Hax-1, which might be explained by 
its significantly emerging role as an anti-apoptotic regulator [208-212]. 
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1.8 EspO : A “LifeGuard” In Enteric Bacteria 
 
The genome of EHEC O157:H7 contains two espO genes (espO1-1 and espO1-2), 
which share 58% amino acid identity (Figure 15.D) [213]. Additionally, espO genes were 
identified in the non-O157 strains, O111:H-, O103:H2 and O26:H11 (See Chapter 3). The 
two EspO proteins are encoded by the genes ECs1567 and ECs1821 of EHEC O157:H7 
strain Sakai, which are located in two different EELs within lamboid prohpages Sp6 and 
Sp9 respectively (Figure 15) [213]. Although, EPEC strain E2348/69 is naturally espO 
negative, the EPEC clone O55:H7, which is considered a progenitor of EHEC O157:H7, 
contains one espO. 
EspO orthologs exist singly in the A/E mouse pathogen C. rodentium and 
Salmonella strains. EspO in C. rodentium, which is located in close proximity to the 
inflammatory related T3SS effector EspT, shares a 58% amino acid identity with EHEC 
EspO1 (Figure 15.C). The Salmonella orthologs, appear to be closely related with EHEC 
EspO. The S. Typhi CT18 paralog that lacks the C-terminal 18 amino acids shares a 55% 
amino acid identity with EHEC EspO1 whereas SopO in S. Typhimurium SL1344 shares a 
68% protein identity (Figure 15.D). On the contrary, the EspO ortholog OspE, which is 
highly conserved in Shigella strains, is distantly related to EHEC EspO1. Sequence 
alignment of EHEC EspO1 and OspE1 (S. flexneri) revealed 30% protein identity (Figure 
15.D).  
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Figure 15. EspO Genome Organisation and Alignment 
Genome organisation of EHEC O157:H7 strain Sakai EspO1 (A) and EspO2 (B) and EspO 
from C. rodentium (C). Amino acid alignment of EspO orthologs (D). Homology shown as 
%age of aa identity compared to EspO1 (EHEC). The red box encloses the tryptophan 
residue (W) required for the EspO-ILK interaction and it is highly conserved among 
orthologs. The yellow boxes enclose tetrapeptides which are predicted to be potential 
caspase-3 recognition sites. 
 
Although, both EspO proteins are translocated via the T3SS, their exact role in EHEC 
/ EPEC infection still remains to be elucidated. Srikanth et al. has recently shown that SipA, 
a S. Typhimurium SPI-1 T3SS effector protein is processed by caspase-3 at a specific 
tetrapeptide recognition site (DEVD) resulting in two functional domains of the protein 
[65]. This caspase-3 motif is common within T3SS effectors in S. Typhimurium but it  also 
appears to be a shared mechanism between enteric pathogens since potential caspase-3 
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cleavage sites were predicted to exist in T3SS effector proteins from S. flexneri and EPEC. 
Using an online server that predicts caspase cleavage sites (CASVM, 
http://www.casbase.org), we identified potential caspase-3 motifs, which are predicted to 
exist in the EspO family of effectors (Yellow boxes in Figure 15.D). In EHEC EspO1 and 
EspO2 the tetrapepdite sites CNVD (position 42) and CSFD (position 55)  were predicted. 
SopO from both S. Typhimurium and S. Typhi was also predicted to have at position 55 a 
potential caspase-3 cleavage site (CSYE) and OspE from S. flexneri has a potential site at 
position 34 (VTTD). However, these potential cleavage motifs still need to be confirmed 
whether they are functionally active.   
Recently, Kim et al. reported that OspE and its orthologs bind integrin-linked kinase 
(ILK), which in turn, enhances the stability of the integrin-containing adhesion sites and 
blocks cell detachment [130]. This strategy keeps infected cells strongly adhered to the 
underlying extracellular matrix allowing the bacteria to establish and maintain their 
infective niche. This interaction was abolished when W68, which is conserved amongst the 
EspO orthologs, is substituted with alanine (W68A) (Figure 15.D). Ectopic expression of 
OspE facilitated focal adhesion formation, which reinforced cell adhesion. Consistently, 
HeLa cells infected with Shigella ∆ospE induced significantly greater cell detachment 
compared to infection with the parental wild type strain or the mutant complemented with 
the wild type ospE gene, whereas OspEW68A failed to complement the mutant. In addition, 
EspO2 only was also shown to localise in the cytoplasm, where it mediates the stress fibers 
induced by the RhoA GEF activity of EspM2 via a direct interaction [214]. This further 
enables EspO2 to stabilise the formation of focal adhesions.  
In this project we identified Hax-1 as a novel protein partner of the family and we 
further investigated the role of EspO in apoptosis to elucidate a cytoprotective role in cell 
death induced by multiple pro-apoptotic compounds. Furthermore, Hax-1 depletion of HeLa 
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cells by siRNA techniques showed that the anti-apoptotic activity of the EspO orthologs is 
Hax-1 dependent. Taken together with previous findings, the results suggest an important 
contribution of the EspO orthologs in cell survival, which involves both cell attachment and 
inhibition of programmed cell death.  
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1.9 Aims 
 
The aim of the project is to elucidate the exact role of the T3SS EspO family of 
effectors in EHEC, Shigella, Salmonella spp. and in C. rodentium in-vivo model of 
infection. The research interests lie mainly within the areas of novel protein partner 
identification, intracellular localisation and function of the EspO family (Figure 16). 
 
 
Figure 16. Research Strategy 
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2 Chapter 2 : Materials and Methods 
 
2.1 Bacterial strains and growth conditions 
 
Bacterial strains used in this project are listed in Table 4.  Strains were maintained on 
Luria–Bertani (LB) broth or agar supplemented with ampicillin (100 µg/ml), 
chloramphenicol (25 µg/ml) or kanamycin (50 µg/ml), when necessary.  
 
2.2 Molecular Biology techniques 
 
2.2.1 Cloning 
 
Plasmids and primers used in this study are listed in Table 5 and 6 respectively. 
Standard molecular biology techniques were used for all constructs. Inserts were amplified 
using the KOD Hot Start DNA Polymerase using the appropriate reactions for PCR (Table 
1).  
 
Reagent Amount (µl) 
dH2O 34 
10x Buffer 5 
MgSO4 3 
dNTPs 5 
Forward Primer (100pmol/µl) 0.5 
Reverse Primer (100pmol/µl) 0.5 
Genomic DNA 1 
KOD DNA polymerase 1 
 
Table 1. PCR Reactions for KOD Hot Start DNA Polymerase 
 
 64 
The cycling conditions for the PCR were used according to the amount of the 
starting template, the size of the primers and the size of the target sequence. The cycling 
conditions for primers with a size of 20-25 bp used to amplify a target size of 1000 bp from 
a template with high number of copies, were 95°C for 2 mins to activate the polymerase, 
95°C for 2 sec. to denature, 55°C for 10 sec. to anneal, 70°C for 20 s/kbp to extend and the 
cycles were repeated 30 times. The PCR product was purified to remove dNTPs, primers 
and enzymes using the PCR purification kit (Qiagen) and checked on an agarose gel (1% 
agarose and 5% SYBR Safe Invitrogen).  
The vector and PCR product were digested with the appropriate restriction enzymes 
in a 50 µl reaction mix (Table 2). The reaction mix was incubated at the appropriate 
temperature required for the enzymes to work optimally and allowed for 1-2 hours. 
 
Reagent Low Copy Plasmid High Copy Plasmid PCR Product 
dH2O 0 13 13 
Vector/PCR product 42.5 29.5 29.5 
10x Buffer 5 5 5 
BSA 0.5 0.5 0.5 
Restriction Enzyme 1 1 1 1 
Restriction Enzyme 2 1 1 1 
 
Table 2. Restriction digest of vector and PCR product 
Restriction enzymes, BSA and the appropriate buffer for each enzyme were purchased from 
NEB Biolabs. Amount for each reagent is shown in µl.  
 
Alkaline phosphatase was added to prevent the vector from ligating to itself. 1 µl of 
alkaline phosphatase (NEB) was added to the restriction digest following digestion and 
incubated at 37ºC for 15 minutes. Digested products were run on agarose gel and then 
excised for purification with the Gel extraction kit (Qiagen). The purified digested PCR 
product was then ligated with the purified digested vector using 2 µl 10x T4 ligase buffer 
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(NEB), 1 µl of T4 ligase and the appropriate amount of insert and vector calculated for 3:1 
ratio according to the formula Insert Mass (ng) = 3 x (Insert Length / Vector Length) x 
Vector Mass (ng). The ligation mix was incubated in 16 ºC overnight or 1 hour at room 
temperature. The ligation mix was then transformed in chemically competent Top10 E. coli 
bacteria as explained below (See Bacterial Transformations). The transformations were 
incubated on selective plates at 37ºC over night and screened by colony PCR using the Red 
Taq Ready Mix PCR Reaction (Sigma). Positive clones were grown in 5 mL LB broth with 
the appropriate antibiotic at  37ºC, 250 rpm over night and centrifuged at 4000 rpm for 15 
min to collect the pellet for purification.  
Minipreps were performed with the appropriate Qiagen kit. The pellet was 
resuspended in 350 µl of buffer P1 (25mM Tris-pH8.0, 50mM glucose, 10mM EDTA, 
5mg/ml lysoszyme, 200ug/ml RNAse A) and 250 µl buffer P2 (0.2M NaOH, 1% SDS) was 
added for lysis. 250 µl of buffer P3 (K+acetate pH 4.8) was added for neutralisation and 
precipitated samples were centrifuged at 13000 x g for 10 mins to collect the supernatant 
(SN). The SN was transferred in a spinning column to collect the DNA by centrifugation at 
13000 x g for 1 min. The samples were washed with 900 µl of 70% ethanol and columns 
were centrifuged at 13000 x g for 1 min. Centrifugation was repeated to completely remove 
residual ethanol and then 50 µl of sterile MilliQ H2O was added. The columns were allowed 
to stand for 1 min and then centrifuged for 1 min to collect the purified DNA. The 
concentration of DNA was determined by spectrophotometry (NanoDrop) and samples were 
sent for sequencing to ensure successful cloning.  
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2.2.2 Bacterial Mutations 
 
EHEC EDL933 single and double espO mutant strains were constructed using the 
one-step PCR λ-red-mediated mutation protocol [215]. Disruption of espO1 was performed 
with a chloramphenicol resistance containing cassette generated with primers c1 and c2 
(Table 6) using pKD3 as a template.  For espO2, a kanamycin resistance containing cassette 
was generated with primers k1 and k2 using pSB315 as a template. The PCR product of 
each resistance cassette contained 50 bp of the appropriate espO gene and was transformed 
into strains harbouring pKD46 (λ-Red recombinase expression plasmid). Mutants were 
selected on LB plates containing the appropriate antibiotic and further confirmed by PCR.  
 
2.2.3 Site-Directed Mutagenesis 
 
The QuickChangeII Site-Directed Mutagenesis kit (Stratagene) was used for single 
amino acid changes or point mutations. Two complimentary oligonucleotides containing the 
desired mutation were synthesised and the appropriate PCR reactions were prepared (Table 
3) 
Reagent Amount (µl) 
10x Reaction buffer 5 
dNTP mix 1 
Double-stranded DNA template 1 
Forward primer (100pmol/µl) 0.5 
Reverse primer (100pmol/µl) 0.5 
dH2O 41 
PfuUltra HF DNA Polymerase 1 
Table 3. Site-Directed Mutagenesis PCR Reaction 
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 The appropriate cycle parameters for the PCR were adjusted according to the type of 
mutation desired (e.g. 12 cycles for point mutations) and the length of the plasmid used in 
the reaction. The PCR product is treated with Dpn I endonuclease to digest the parental 
DNA template and therefore, select for the vector DNA containing the mutation. The 
resulting mutated vector was then transformed into chemically competent Top10 E. coli 
bacteria and minipreps were performed on positive clones to extract plasmid for further 
confirmation of the desired mutation by sequencing.  
 
2.3 Bacterial Transformations 
 
Chemically competent cells were prepared for heat shock transformation by growing 
cells until an OD600 of 0.5, and after a centrifugation at 5000 rpm for 10 min at 4°C the cells 
were resuspended in 25 mL of cold 50 mM CaCl2. Following, 30 min incubation on ice the 
cells were further centrifuged and resuspended in 2.5 mL of cold CaCl2. The cells were 
further incubated for 1hr on ice.  
Transformation by heat shock was done by adding 10 ng of DNA in 100 µl of 
competent top10 E. coli bacteria or 200 µl of EHEC EDL933 or EPEC E2348/69 lab strain 
competent bacteria and incubated for 30 min on ice. Heat shock was performed by 
incubating 2 min at 42°C followed by 10 min on ice. 900 µl of SOC medium was added and 
bacteria were allowed to recover for 1 hr in 37 °C. An overnight incubation on selective 
media allowed the selection of positive clones. 
Electrocompetent cells were prepared by growing cells as above and then incubating 
for 15 min at 4°C. After an initial centrifugation at 4000 rpm at 4°C for 15 min, the cells 
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were washed with 50ml of cold H2O 15% glycerol. This step was repeated and the pellet 
was resuspended in 1mL of cold H2O 15% glycerol. Finally, the cells were spun once more 
in order to increase concentration by resuspending in a final volume of 100 µl in cold H2O 
15% glycerol. 10 ng of concentrated PCR product was electroporated into the 100 µl of 
electrocompetent cells. 700 ml of SOC medium was added and bacteria were grown for 
1h30 at 37°C. Selection of positive clones was done by plating on selective media and 
further confirming by colony PCR. 
 
2.4 Yeast transformations 
 
S. cerevisiae wild type yeast strain AH109 was grown overnight at 30°C in YPDA 
broth (1% w/v Bacto yeast extract, 2% w/v Bacto peptone and adenine 80 mg/l) and then 
centrifuged at 4000 rpm for 15 min. The pellet was washed twice with sterile H2O and 
resuspended in the transformation mix containing 50% w/v PEG 3350, 36µl 1M LiAc, 50µl 
Herring sperm DNA (2 mg/ml), 34µl sterile H2O and 1µg of the appropriate plasmid to be 
transformed [216, 217]. The mixture was incubated at 30°C for 30 min and then heat shock 
was applied by incubating at 42°C for 20 min. Sample was centrifuged at 13000 x g for 15 
sec. and resuspended in 1mL sterile H2O. 100µl of each sample was plated onto appropriate 
selective plates.  
 
2.5 Yeast two-hybrid screening 
 
A yeast two-hybrid (Y2H) screen was performed using EHEC EDL933 EspO1 as a 
bait with the Matchmaker Pretransformed Normalised HeLa cDNA library (Clontech) 
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according to the manufacturer’s instructions. In a Y2H assay the bait protein (EspO1) is 
fused to the Gal4 DNA-binding domain (DNA-BD) and the prey proteins (HeLa cDNA 
library) are fused to the Gal4 activation domain (AD). If the bait protein interacts with a 
prey protein, the DNA-BD and AD are brought into close proximity to initiate transcription 
of reporter genes, which are under the control of Gal4 upstream activating sequence (UAS). 
These include genes encoding essential amino acids e.g. histidine (HIS3) and adenine 
(ADE2) but also enzymes like α-galactosidase (MEL1) and β-galactosidase (LacZ) that turn 
yeast colonies blue when the chromagenic substrate X-α-Gal is present in the medium.  
The yeast strain AH109 was transformed with the bait construct pGBKT7-EspO1 
using the LiAc method described above and mated with the yeast strain Y187 
pretransformed with the pGADT7 Rec plasmid carrying the HeLa cDNA library. The 
mating happens overnight when the two yeast strains are incubated in appropriate broth 
medium (YPDA) at 30°C and slow shaking (50 rpm). Positive clones were selected by 
plating on quadruple dropout media (QDO) or high-stringency SD / DO media (0.67% 
Yeast nitrogen base without amino acids, 2% agar and 10x Dropout Solution lacking Trp, 
Leu, His and Ade). Tryptophan and leucine act as a selection for the bait pGBKT7 and prey 
pGADT7 vectors respectively whereas histidine and adenine are two of the reporter genes 
that select for positive protein interaction. Clones were also plated onto low stringency or 
double dropout (DDO) SD media (SD/-Leu/-Trp) as a selection of only diploids with both 
prey and bait plasmids. Colonies were re-streaked on QDO to ensure expression of reporter 
genes and therefore, positive interaction. The pGADT7 cDNA inserts from all remaining 
colonies were amplified using the AD-LD primers (Clontech). The PCR products were then 
sequenced and identified using Blastn and Blastx. 
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Figure 17. Yeast Two-Hybrid Assay (Designed by author) 
Illustration of a yeast two-hybrid (Y2H) assay. The bait vector pGBKT7 expressing EspO1 
fused to Gal4 DNA-binding domain (GAL4 DBD) is transformed in yeast strain AH109. 
The yeast strain Y187, pretransformed with the HeLa cDNA library, is incubated with 
AH109 to allow mating to occur overnight at 30oC and slow shaking at 50 rpm. The 
overnight culture is plated onto high stringency medium or quadruple dropout media (QDO) 
to select for diploid yeast cells containing both bait and prey vectors and a positive protein 
interaction. If there is a successful interaction between the bait and a prey protein, the Gal4 
activation domain (GAL4 AD), which is fused to the prey protein is brought into close 
proximity with the GAL4 DBD to initiate transcription of the reporter genes and hence, 
allow blue colonies to grow on QDO. The illustration was designed by the author for this 
study.  
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2.6 Cell lines and growth conditions 
 
HeLa ATCC were grown in flasks containing DMEM (1 g/l glucose) supplemented 
with 2mM Glutamax and 10% FCS at 37oC in 5% CO2. Adherent cells were washed with 
sterile PBS and brought into suspension with trypsin/EDTA at 37oC for 10 mins. Equal 
amount of fresh serum containing medium was added to neutralise the trypsin and 250 µl of 
cell suspension were mixed with an equal volume of Trypan Blue to obtain a dilution factor 
of 2. 10 µl of the mixture were used to fill the chambers of the haemocytometer to count the 
cells with a light microscope at x20 mignification. The number of viable (bright cells) and 
non-viable (stained blue) were counted and the concentration of cells was calculated 
[concentration of viable cells per ml = (Total viable cells / Number of squares) x Dilution 
Factor (2) x Correction Factor (104) ]. The remaining suspension was centrifuged at 1000 x 
g for 3 mins and cell pellet was resuspended in fresh serum containing DMEM. Cells were 
seeded 24h or 48h prior to transfection or infection onto 24-well plates containing glass 
coverslips at a density of 5x104 per well unless stated otherwise.  
 
2.7 Transfections 
 
Transfections were performed with FuGENE6 (Roche) or GeneJuice (Novagen) at 1:3 
ratio (reagent:DNA) in Opti-MEM (Invitrogen) as recommended by the manufacturers. In 
the case of co-transfection, cells were transfected with equal amounts of the two plasmids. 
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The cells were incubated with the transfection:DNA mix for 24 hours in a 5% CO2 incubator 
at 37oC and then washed in PBS and fixed in 3 % PFA.  
 
2.8 Infection of HeLa cells 
 
EHEC was grown o/n in LB with the appropriate antibiotics when necessary. Bacterial 
growth was diluted in 1:500 DMEM with antibiotics and bacteria were statically incubated 
o/n at 37oC, 5% CO2. Expression was induced for 30 min with 0.1mM IPTG when required. 
HeLa growth medium was replaced with 0.5 mL warm DMEM without FCS for 30 mins 
prior to infection and cells were infected approximately at 1 x 109 cfu. Infected plates were 
centrifuged for 5 min at 1000 rpm to increase bacterial attachment and incubated at 37oC, 
5% CO2 for 5h. After 2h 30 min of incubation, HeLa cells were washed three times with 
PBS to remove non-adherent bacteria and warm DMEM added for the remaining 
incubation.  
Overnight EPEC cultures were prepared in LB with the appropriate antibiotic. On the 
day of infection, the bacteria were primed by diluting the o/n culture 1:50 in DMEM 1g/l 
glucose. Priming was allowed for 3h at 37oC, 5% CO2 under static conditions. Bacterial 
cultures were induced with 0.1mM IPTG for 30 min prior to infections. HeLa cells were 
washed with PBS and 0.5 mL of the primed overnight culture was added in the wells. 
Infections were allowed to proceed for 1h before adding 300 µg/ml gentamicin to kill 
extracellular bacteria and incubation continued for a further 1-2hs. All cells were washed 
with PBS and fixed with 3% PFA at RT for 15 min. 
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2.9 Scanning Electron Microscope 
 
Tissue samples from mouse in-vitro cultures (mIVOC) were fixed in 2.5% 
glutaraldehyde in phosphate buffer (PBS). After fixation tissues were incubated in PBS for 
1h30 and then fixed with secondary fixative 1% osmium tetroxide (OsO4) in PBS for 30 
mins. Samples were washed with PBS followed by distilled water prior to ethanol 
dehydration; a sequential 10 min treatment of samples with increasing concentration of 
aqueous ethanol solutions. Tissue samples were dried using Emitech K850 Critical Point 
drier according to manufacturer’s instructions and mounted on aluminium stubs for 
gold/palladium mix coating using Emitech Sc7620. Samples were examined using Jeol 
JSM-6390 Scanning Electron Microscope. 
 
2.10 Immunofluorescence staining 
 
After PFA fixation, cells were washed with PBS and remaining PFA was neutralised 
with ammonium chloride. Cells were then permeabilised with 0.1% Triton X-100 in PBS for 
4 mins at RT, washed twice in PBS, and blocked in 3% BSA-PBS for 20 mins. Coverslips 
were incubated with the appropriate primary antibody diluted in blocking agent for 45 min 
at RT [mouse α- Myc (1:500 - Sigma), mouse α- Hax (1:50 - BD), rabbit α- cleaved Caspase 
3 (1:100 – BD), mouse α- Cytochrome -c (1:100 - Merck), rabbit α- O157 (1:500) for EHEC 
and rabbit α- O127 (1:500) for EPEC]. The cells were washed three times with PBS for 15 
mins and stained with appropriate secondary antibodies Donkey α- mouseFITC, α- rabbitFITC, 
α- rabbitCy5 at 1:200 (Jackson Immunoresearch) or DAPI for DNA staining (1:500). When 
necessary a directly conjugated α- mycFITC (1:200 – Sigma) was added for a third antibody 
incubation. Coverslips were washed three times in PBS, once in distilled H2O and mounted 
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on glass slides using ProLong Gold reagent (Invitrogen). Immunoflourescent staining was 
visualised with a Zeiss AxioImager fluorescence microscope (M1 and Z1) by Carl Zeiss. 
Images were analyzed with the AxioVision Release 4.8 and Fiji softwares.  
 
2.11 Microscopy and Imaging 
 
Immunoflourescent staining was visualised with a Zeiss AxioImager fluorescence 
microscope (M1 or Z1) by Carl Zeiss. Images were analyzed with the AxioVision Release 
4.8 software and the open source image processing Fiji / Image J package (http://fiji.sc/Fiji). 
Appropriate deconvolution algorithms were used to optimise the point spread function 
(PSF), which is the point source of light that passes through a lens and describes the 
diffraction of light in an optical system. A useful PSF results from acquiring and processing 
multiple z-stacks (i.e. multiple images of different focus). For best results, z-stacks for all 
images were acquired above and below the object of interest (20-30 z-stacks). The 
appropriate z-step interval can be set to automatic and calculated by the Zeiss AxioImager 
software but can be also calculated manually using the Abbe-Rayleigh diffraction limit 
equation:  z-step interval (nm)  =  (emission wavelength x refractive index of the mounting 
medium) / (numerical aperture of the objective2). The z-step interval was ~ 250nm for all 
images. For deblurring / deconvolution the “Regularized Inverse Filter” algorithm which is 
a 3D deblurring method from Z-stacks with Nyquist oversampling (Nyquist sampling 
theorem is used in the process of converting a signal into numeric sequence). The processed 
images were exported from the AxioVision or Fiji softwares in appropriate file formats (i.e. 
.jpg or .png). The Fiji software was used to calculate scale bars for IF images. The JACoP,  
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Coloc2 and Colocalisation Threshold plugins were used in Fiji to quantify colocalisation 
and perform the statistical anylisis. 
 
2.12 Western Blots 
 
Cells were lysed with RIPA buffer [150mM sodium chloride, 1.0% NP-40, 0.5% 
sodium deoxycholate, 0.1% SDS, 50mM Tris – pH 8.0, with complete, mini, EDTA-free 
protease inhibitor cocktail (Roche) and phosphatase inhibitors (2mM Na3VO4, 10mM NaF 
and 1mM PMSF)]. Protein concentration was determined using the BCA assay 
(ThermoScientific) according to the manufacturer’s manual. Samples were denatured with 
Laemmli buffer and heated at 95 oC for 5 mins. Samples were separated by SDS-PAGE and 
gels were either stained with Coomassie Brilliant Blue R-250 or transferred to PVDF 
membrane. Membranes were blocked in 5% milk or BSA – PBST for 1 hour and then 
incubated in primary antibody overnight at 4 oC under agitation (mouse α- Hax (1:500 - 
BD), mouse anti- α-Tubulin (1:2000 – Sigma) and mouse α- MBP (1:1000 – NEB) followed 
by HRP-conjugated secondary antibodies (1:2500 – Jackson Immunoresearch). HRP was 
detected with ECL+ Detection Kit and visualised with LAS-3000 Imaging System (Fuji).  
 
2.13 Pull-Downs 
 
EspO MBP fusion constructs in Top10 E. coli were grown to an OD of 0.5-0.6 at 37oC 
or 30oC in LB broth with the appropriate antibiotic and then induced with 0.3 mM IPTG for 
2 or 3 hours. Cells were harvested, resuspended in Column Buffer (20 mM Tris-HCL, 200 
mM NaCl and 1 mM EDTA) and sonicated for 5 min in short pulses of 15 sec. Insoluble 
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protein was removed by centrifugation at 9000 x g for 30 mins and soluble protein allowed 
to bind onto an amylose column. Bound protein was washed three times with 2ml of 
Column buffer with 1mM DTT before eluting with maltose and analysed by SDS-PAGE 
and Coomassie Brilliant Blue staining. 
2mL of bacterial lysate (MBP:EspO or MBP:lacZ control) were added to 1mL cleared 
amylose beads. HEK293 cells grown at suspension were collected by centrifugation at 
2x106 cell density and lysed with 5 mL RIPA buffer [150mM sodium chloride, 1.0% NP-40, 
0.5% sodium deoxycholate, 0.1% SDS, 50mM Tris – pH 8.0, with complete mini- protease 
and phosphatase inhibitors EDTA-free (Roche)]. 1mL of HEK293 cell lysate was added to 
appropriate samples. Samples were incubated on a rotating wheel overnight at 4 oC. 
Supernatant was removed by centrifugation and beads were washed 3x in column buffer. 
Bound proteins were eluted in 10mM maltose in column buffer on ice for 20 min and 
analysed by SDS-PAGE and western blot.  
 
2.14 Apoptosis experiments 
 
Apoptosis was induced in HeLa cells 24 hours after transfection with 1µM 
staurosporine (Sigma) for 3 hrs, 10µg/ml tunicamycin (Sigma) for 16-24hrs or 1µM 
thapsigargin (Sigma) for 4hrs. Cells were fixed with 3% PFA and stained with cleaved 
caspase-3 and condensed nuclei and/or TUNEL (Promega). TUNEL staining was performed 
according to the users manual; apoptotic nuclei were stained with the fluoroscein-12-dUTP 
supplied and healthy nuclei were stained with DAPI (1:500). 100 transfected cells per 
condition were counted for staurosporine and tunicamycin and 50 cells counted for 
thapsigargin; all of them assessed for markers of apoptosis.   
 77 
2.15 Infection of mice with C. rodentium 
 
C. rodentium wild-type (ICC169), espO mutant (prepared with one-step PCR λ-red-
mediated mutation protocol) and mutant strain complemented with pACYC-espO or 
espO(W77A) were pelleted by centrifugation and resuspended in PBS. Specifc-pathogen-
free 6- to 8- week-old C57BL/6 mice (Harlan, UK Ltd.) were inoculated by oral gavage at 
2x109 cfu in 200 µl PBS. All animals were housed in individual cages with sterile bedding 
and free access to sterilized food and water. Two independent experiments were performed 
using four mice per group. The viable counts of each inoculum were determined by plating 
dilutions on selective plates. Stool samples were collected daily up to 18 days post-
inoculation. The viable count per gram of stool was determined by plating serial dilutions of 
stool samples onto selective media.  
Hyperplasia was assessed 18 days post inoculation by collecting segments of the 
cecum, rinsed and fixed in 10% formalin. Fixed tissues were then processed, paraffin 
embedded, sectioned at 5 µm and stained with hematoxylin and eosin (H&E). The length of 
at least four well-oriented crypts was evaluated for each section and a non-parametric 
analysis of variance (ANOVA) was performed using GraphPad Prism Statistical Software. P 
values of ≤0.05 were considered significant.  
Snap-frozen colonic tissues were sectioned with a cryostat to a thickness of 5 µm. The 
sections were then mounted on polysine slides and air dried over night before acetone 
fixation. The sections were air dried for 1 hour and re-hydrated in Tris-buffered saline 
(TBS) for 5 mins. Incubation with the appropriate antibodies (Ly6 for neutrophils and CD4 
antibody for staining CD4+ T cells) at a dilution 1:50 followed for 1 hour. The sections 
were then washed in TBS and biotinylated anti-`rat immunoglobulin G was added at a 
dilution 1:200. 0.1% avidin-peroxidase (Sigma-Aldrich, Dorset, United Kingdom) was then 
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added at 1:200 and left for 30 min before further washing and treatment with 
diaminobenzadine substrate (Sigma-Aldrich) for 5 min. Sections were then counterstained 
with Mayer's hematoxylin (Sigma-Aldrich) for 30 s, dipped in acid alcohol, and washed in 
tap water for 5 min. Dehydration followed through an ethanol gradient of 70%, 90%, and 
100% solutions (2 min each). Stained cell populations were counted in five randomly 
selected fields per section, and data were expressed as the number of Neutrophil or T cells 
per 250 µm2 of lamina propria.  
 
2.16 siRNA experiments 
 
Cells were seeded at 5x103 cells/well in 24-well plates with coverslips 24h prior to the 
introduction of siRNAs (Dharmacon). Cells were transfected with 20µM Hax-1 targeted 
siRNA according to the HiperFect user manual. Optimum knockdown of Hax-1 was seen 
after 72 hrs of incubation as confirmed by western blots analysis. The cells were then used 
for the apoptosis experiments as described above and 100 transfected cells were assessed for 
apoptosis per condition. 
 
2.17 Statistical significance 
 
Results from apoptosis experiments include three biological replicates (each 
biological consists of two technical replicates) and were analysed for statistical significance 
using the GraphPad Prism Statistical Software Version 6 (GraphPad Software Inc.,San 
Diego). Results are represented as means ± standard deviations analysed by a two-tailed 
unpaired t-test with equal SD.  
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2.18 Diagramatic illustrations 
 
Illustrations prepared for this study were designed by the author using Adobe 
Illustrator and Microsoft Office Power Point. 
 
 
 
Table 4. List of strains 
 
ICC Strains Description Source/Reference 
 EDL933  EHEC O157:H7 stx- ATCC 700927 
 EDL933 ∆ espO1-1 Single espO1-1 deletion mutant in EHEC EDL933 (CmR) This study 
 EDL933 ∆ espO1-2 Single espO1-2 deletion mutant in EHEC EDL933 (KnR) This study 
 EDL933∆espO1-1∆espO1-2 Double espO deletion mutant in EHEC EDL933 (CmR, KnR) This study 
 EDL933∆espO1-1∆espO1-2 
pSA10:: espO1-1 
Complemented double mutant overexpressing espO1-1 with c-
terminal HA-tag This study 
 E2348/69 wt EPEC O127:H6 wild type [218] 
303 E2348/69 ∆nleH1 ∆nleH2 EPEC O127:H6 double nleH mutant [48] 
 E2348/69∆nleH1∆nleH2 
pSA10::espO1-1 EPEC O127:H6 overexpressing espO1-1 (untagged) This study 
 E2348/69∆nleH1∆nleH2 
pSA10::espO1-1W77A EPEC O127:H6 overexpressing espO1 W77A (untagged) This study 
169 C. rodentium wt Wild type strain  
 
C. rodentium ∆ espO Single espO mutant 
This study 
 C. rodentium ∆ espO 
pACYC::espO Complemented mutant with full length espO 
This study 
 
C. rodentium ∆ espO 
pACYC::espOW77A 
Complemented mutant with Trp deletion mutant at position 72 
of espO (equivalent of W77A in EspO1-EHEC and W68A in 
OspE – S. flexnerie) 
This study 
 
AH109 
S. cerevisiae HIS3, ADE2, lacZ, and MEL1 reporters for 
interaction, and TRP1 and LEU2 transformation markers Clontech 
 
Y187 
S. cerevisiae lacZ, and MEL1 reporters for interaction, and 
TRP1 and LEU2 transformation markers Clontech 
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Table 5. List of plasmids 
 
pICC Name  Description Reference 
 pKD4 oriRg, blaM, KanR cassette flanked by FRT sites [215] 
 pKD3 oriRg, blaM, CmR cassette flanked by FRT sites [215] 
 pKD46 ori101, repA 101 (ts), araBp-gam-bet-exo, blaM [215] 
 pRK5::myc Mammalian expression vector with N-term Myc tag Clontech 
563 pRK5:: gfp Full-length GFP  [48] 
 pRK5::myc- espO1-1 Full length espO1-1 (EHEC EDL933)  This study 
 pRK5::myc- espO1-2 Full length espO1-2 (EHEC EDL933) This study 
 pRK5::myc- espO Full length espO (C. rodentium ICC168) This study 
 pRK5::myc- sopO (TYM) Full length ospE1 (S. Typhimurium) This study 
 pRK5::myc- ospE1 Full length ospE1 (S. flexnerie) This study 
 pRK5::myc- espO1-1 (W77A) Trp deletion mutant at position 77 of espO1-1 (EHEC) This study 
 pRK5::myc- ospE1 (W68A) Trp deletion mutant at position 68 of ospE1 (S. flexnerie) This study 
 pRK5::myc- sopO (TY) Full length sopO (S. Typhi) This study 
512 pRK5::myc- nleH1 Full length nleH1 (EPEC E2348/69) [48] 
 pCDNA::Flag- espO1-1 Full length espO1-1 (EHEC EDL933) This study 
 pCMV::myc- hax-1 Full length hax-1 fused to myc tag. [205] 
 
pGADT7-Rec Y2H vector containing GAL4 DNA activation domain 
(GAL4-AD) Clontech 
 pGADT7-Rec::hax-1 
Full length hax-1 fused to GAL4-AD (Y2H) This study 
 
pGBKT7 Y2H expression vector with GAL4 DNA binding 
domain (GAL4-BD) Clontech 
 pGBKT7::espO1-1 Full length espO1-1 fused to Gal4 DNA-BD (Y2H) This study 
 pGBKT7::espO1-2 Full length espO1-2 fused to Gal4 DNA-BD (Y2H) This study 
 pGBKT7::espO Full length espO (C. rodentium ICC168) This study 
 pGBKT7::sopO (TYM) Full length ospE1 (S. Typhimurium) This study 
 pGBKT7::sopO (TY) Full length ospE1 (S. Typhi) This study 
 pGBKT7::ospE1 Full length ospE1 (S. flexnerie) This study 
 pGBKT7::espO1-1 (W77A) Trp deletion mutant at position 77 of espO1-1 (EHEC) This study 
 pGBKT7::ospE1 (W68A) Trp deletion mutant at position 68 of ospE1 (S. flexnerie) This study 
 pGBKT7::espO1-1 (1-45) N-terminal deletion mutant of espO1-1 (EHEC) This study 
 pGBKT7::espO1-1 (45-91) C-terminal deletion mutant of espO1-1 (EHEC) This study 
 pGBKT7::espO1-1 (1-73) C-terminal 18 aa deletion mutant of espO1-1 (EHEC) This study 
 pGBKT7::espO1-1 -myc C-terminal tagged espO1-1 (EHEC) This study 
 
pSA10 
pKK177-3 induced expression vector containing lacI 
gene [219] 
 pSA10:: espO1-1 Derivative of pSA10 expressing espO1-1  This study 
 pSA10:: espO1-1 (W77A) Derivative of pSA10 expressing espO1-1 (W77A) This study 
 pACYC184 orip154, CmR, TcR NEB 
 pMAL::MBP- lacZ MBP tag expression vector NEB 
 pMAL::MBP- espO1-1 Full length espO1-1 fused to MBP  This study 
 pMAL::MBP- espO1-2 Full length espO1-2 fused to MBP  This study 
 81 
 pCDNA3.1::HA-CREB3 Mammalian vector expressing ER marker CREB3 This study 
 pACYC184::espO In-vivo espO mutant complementation (C. rodentium) This study 
 
pACYC184::espO (W77A) 
In-vivo Trp deletion mutant at position 72 of espO 
mutant complementation (C. rodentium) This study 
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Table 6. List of primers (RE sites underlined and Point mutations or insertions in bold) 
 
No. Name Nucleotide Sequence (5'-3') 
1 pSA10-EspO1-F GCTGAATTCATGCCATTTTCAATCAAAAAC 
2 pSA10-EspO1-HA-R GCTCTGCAGCTATGATTTGTTTGTATTATTTG 
3 pSA10-EspO1-R GCTCTGCAGTTCTTTTGTGTTGTGTATC 
4 pRK5-EspO1-F TTGAATTCATGCCATTTTCAATCAAAAAC 
5 pRK5-EspO1-R CCAATGCACTGCAGTTAAGCGTAGTCTGGGACGTCGTATGGGTATTCTTTTGTGTTGTGTATC 
6 pRK5-EspO2-F TTGAATTCATGCCATTTTCAATAAAAAG 
7 pRK5-EspO2-R CCAATGCACTGCAGTTAAGCGTAGTCTGGGACGTCGTATGGGTATGATTTGTTTGTATTATTTG 
8 pRK5-OspE1-F GCTGGATCCGGAGCACTTACACAAACTATATTCCC 
9 pRK5-OspE1-R GCTGAATTCTCAGAAATCAGAATACCGTTGGCTTT 
10 pRK5-SopO(TYM)-F GCTGGATCCGGAGCACCATTTTCAATCAAAAAC 
11 pRK5-SopO(TYM)-R GCTGAATTCTCATTCTTTTGTGTTGC 
12 pRK5-EspO(CR)-F GCTGGATCCGGAGCACCATTGTCAATAAGAAATATAT 
13 pRK5-EspO(CR)-R GCTGAATTCTCAGGATTTATTTGAGTTATTAATCTCG 
14 pRK5-SopO(TY)-F GCTGGATCCGGAGCACCATTTTCAATCAAA 
15 pRK5-SopO(TY)-R GCTGAATTCTGATGCTGATAATTTTAGTCGTG 
16 EspO1(W77A)-F GTTACTGAGATGACAGCGCTATCTAAAACTATAG 
17 EspO1(W77A)-R CTATAGTTTTAGATAGCGCTGTCATCTCAGTAAC 
18 OspE1(W68A)-F GCTACAGAAATGCAAGCGTTGACAAAGATAAATG 
19 OspE1(W68A)-R CATTTATCTTTGTCAACGCTTGCATTTCTGTAGC 
20 pGBKT7-EspO1-F TTGAATTCATGCCATTTTCAATCAAAAAC 
21 pGBKT7-EspO1-R CGCGGATCCCTATTCTTTTGTGTTGTGTATC 
22 pGBKT7-EspO2-F TTGAATTCATGCCATTTTCAATAAAAAG 
23 pGBKT7-EspO2-R CGCGGATCCCTATGATTTGTTTGTATTATTTG 
24 pGBKT7-OspE1-F GCTGAATTCCTTACACAAACTATATTCCCTTGTC 
25 pGBKT7-OspE1-R GCTGGATCCTCAGAAATCAGAATACCGTTG 
26 pGBKT7-SopO(TYM)-F GCTGAATTCCCATTTTCAATCAAAAAC 
27 pGBKT7-SopO(TYM)-R GCTGGATCCTCATTCTTTTGTGTTGC 
28 pGBKT7-EspO(CR)-F GCTGAATTCCCATTGTCAATAAGAAATATATTTTC 
29 pGBKT7-EspO(CR)-R GCTGGATCCTCAGGATTTATTTGAGTTATTAA 
30 pGBKT7-EspO1(1-45)-F GCTGAATTCCCATTTTCAATCAAAAACAGATTTTC 
31 pGBKT7-EspO1(1-45)-R GCTCTGCAGTGTATAGCTATCTACATTACATGTT 
32 pGBKT7-EspO1(45-90)-F GCTGAATTCGTGTACCAAAAAAAAGCCTGTA 
33 pGBKT7-EspO1(45-90)-R GCTCTGCAGCTATTCTTTTGTGTTGTGTATCT 
34 EspOΔ18-F CTCTCAGTTACTTAGGAGATGACATGG 
35 EspOΔ18-R CCATGTCATCTCCTAAGTAACTGAGAG 
36 c-terminal myc  pGBKT7- GCAGAACAAAAACTTATTTCTGAAGAAGATCTGTTAGGGATCCGTCGACCTGCAGCG 
37 c-terminal myc  pGBKT7- CTAACAGATCTTCTTCAGAAATAAGTTTTTGTTCTGCTTCTTTTGTGTTGTGTATCT 
38 pGADT7-Hax1-F GCTGAATTCAGCCTCTTTGATCTCTTCCG 
39 pGADT7-Hax1-R GCTGAATTCCTACCGGGACCGGAACC 
40 AD-LD F CTATTCGATGATGAAGATACCCCACCAAA 
41 AD-LD R AGATGGTGCACGATGCACAGTT 
42 pMAL-EspO1-F GCTGAATTCCCATTTTCAATCAAAAACAGATTTTC 
43 pMAL-EspO1-R GCTGGATCCCTATTCTTTTGTGTTGTGTATC 
c1 EspO1 del. F CAACTTATAACGGAATAGCATAAAAACACTTTTCATGGAGCAAAGGAGAAAACATGTGTAGGCTGGAGCTGCT 
c2 EspO1 del. R GTCAGGTGTTTCGGGTCTGTGGCTTTTTGTGTTCTCTGGTAAGTGGTTGCATATGAATATCCTCCTTAGTTCC 
k1 EspO2 del. F CTAAATACATTAAATTGCACTATAAGAGAAAGACATAATGTGAGGATAAAATGTGTAGGCTGGAGCTGCTTCG 
k2 EspO2 del. R GTTAGGAAGTTATTCATGGCTAGTGTACCAACTCTTTTCTGGGCTAATAGCATATGAATATCCTCCTTAGTTCC 
44 Ext.- EspO1-F ATAAGCAAGATCCACTTATCAAAAGAGCATTA 
45 Ext.- EspO1-R ACTATCACTTATTTAAGTGATACT 
46 Ext.- EspO2-F AATACCCTGTCGTGCCCATTTTTCCATCGGACGCA 
47 Ext.- EspO2-R CGTTTTTCGTGTCTTTAAGTGAT 
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48 Cm-pKD3-R TTTTGAGGCATTTCAGTCAGTTGC 
49 Kn-pKD4-R CATCGCCATGGGTCACGACGAGAT 
50 pACYC184-EspO-F gctggatcctagAAGAAGGAGATATACCATGCCATTGTCAATAAGAAA 
51 pACYC184-EspO-R gctgtcgacTCAGGATTTATTTGAGTTATTAATCTCGGTC 
52 EspOcr(W77A)-F GCCTCAGAAGCTCAGGCGATGTGCAAAATTATAG 
53 EspOcr(W77A)-R CTATAATTTTGCACATCGCCTGAGCTTCTGAGGC 
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3 Chapter 3 : Novel Interacting Partners 
 
3.1 Distribution of EspO in enteric bacteria 
 
In order to find the prevalence of EspO in enteric bacteria and look at the relationships 
between EspO homologues, we performed EHEC EspO1 amino acid sequence searches 
against translated reference genomic sequences of the Enterobacteriaceae genera using 
TBLASTX of the NCBI database and the relationship between EspO homologs, orthologs 
and paralogs was determined with the TreeView (BioEdit) and visualised as an EspO 
phylogeny of the ClustalW2 (EMBL-EBI) multiple sequence alignments.  
 
 
Figure 18. Phylogram of EspO family members conserved in enteric bacteria.  
Phylogram showing the homologues of the EHEC or EPEC EspO in Shigella and 
Salmonella strains. The phylogram was created with TreeView, BioEdit. 
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Bioinformatic analysis identified EspO primarily in EHEC O157:H7 strains and non-
O157 strains O111:H-, O103:H2 and O26:H11 (Figure 18). EspO orthologs exist singly in 
C. rodentium and Salmonella strains. As shown in the phylogram, the Salmonella orthologs, 
appear to be closely related with EHEC EspO. Only, SopO in S. Paratyphi A and B strains, 
which is a truncated form, seems to be more distant. On the contrary, the EspO ortholog 
OspE, which is highly conserved in Shigella strains, is distantly related to EHEC EspO1 
(Figure 18).  
As previously mentioned, the prototypical EPEC strain E2348/69 is naturally espO 
negative but the EPEC clone O55:H7, which is considered a progenitor of EHEC O157:H7, 
contains one espO. To further understand the prevalence of espO among EPEC strains, we 
performed a mini PCR screen on clinical EPEC isolates using two sets of primers designed 
to detect espO1-1 and espO1-2 from EHEC strain EDL933 and identified espO in 18/72 
EPEC isolates (25%) of serogroups O55 (7/13 - 54%), O26 (2/5 – 40%), O111 (1/5 – 20%), 
O154 (1), O85 (1), O123 (1), O49 (1), O109 (1) and ONT (2) (Table 7). Of note is the fact 
that due to sequence variation the primers used for the screen might not amplify all the espO 
variants. As a positive control we used EPEC O111:H9 strain E110019 whose genome has 
been partially sequenced and revealed the presence of one espO gene. The espO screen and 
bioinformatic analysis indicate that EspO might have an important role in pathogenesis due 
to its relatively high abundance in enteric bacterial pathogens.  
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 Pathotype and serotype (no. of strains) EspO1 EspO2 
   
O55:H7 (1) + - 
O55:H7 (3) - + 
O26:H- (1) - + 
O26:H11 (1) + + 
O154:H9 (1) + - 
ONT:H- (1) + + 
O85:H- (1) + - 
O123:H-(2) + - 
O49:H- (1) + + 
ONT:H7 (1) + - 
aEPEC 
O109:H9 (1) + + 
   
O111:H- (1) + - 
O55:H- (2) + - 
tEPEC 
O55:H6 (1) - + 
 
Table 7. EspO distribution in EPEC isolates 
PCR screen on clinical EPEC isolates using primers designed to detect espO1-1 and espO1-
2 from EHEC strain EDL933. Positive espO strains are shown in the table. The strains are 
divided into atypical EPEC (aEPEC) that include strains lacking the EAF plasmid and 
typical EPEC (tEPEC) that describe strains harbouring the plasmid.  
espO-negative strains are as follows: O104:H2 (2), O2:H49 (2), O26:H- (3), O45:H- (1), 
O111:H- (1), O153:H- (1), OR:H- (1), O13:H- (1), O8 (1), O103:H2 (1), O109:H2 (1), 
O128:H2 (1), O15:H- (1), O55:H- (2), O55:H6 (2), O55:H7 (2), O86:H34 (3), O111:H2 (3), 
O119:H2 (4), O119:H6 (4), O125:H6 (1), O127:H6 (1), O127:H40 (3), O128:H2 (4), 
O128ab:H2 (1), O142:H6 (3), O142:H34 (3). 
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3.2 Identifying novel EspO interacting partners 
 
To identify protein partners interacting with EspO, a yeast two-hybrid screen was 
done with a Matchmaker Pretransformed Normalised Library from HeLa cells and EspO1 
(EHEC) bait construct expressing the full-length protein. The 77 diploid clones, which 
survived after two re-streaks on high-stringency media (QDO) were further confirmed by 
colony PCR. The sizes of the PCR products were in the range of 900bp to 1500 bp (Figure 
19).  
 
Figure 19. PCR confirmation of yeast clones.  
Colony PCR performed on yeast clones grown on high stringency media (QDO). Clone 
numbers in red indicate the PCR products selected for sequencing.  
 
The majority of the clones (53/77) yielded 1.5kb PCR product and six of these 
clones were further confirmed by sequencing. Blastn and blastx algorithms (PubMed) were 
used to analyse the sequencing results, which revealed that the 1.5kb PCR product is Hax-1 
(HCLS associated protein X-1). The clones 25 and 29 (Table 8) appeared to have two 
plasmids and each PCR product yielded from these clones was separately gel purified and 
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sequenced. This is a normal yeast two-hybrid outcome since transformed yeast cells are able 
to accommodate more than one version of a related plasmid. All PCR products of size other 
than 1.5kb were also sequenced (17/77) (Table 8). Another interesting hit, which was 
detected more than once was the DnaJ homolog or Heat shock protein 40 (Hsp40) subfamily 
B.  
 
Table 8. Sequencing results for 27 clones 
 
Clone No. Accession No. Protein 
2 NM_012328.1 Homo sapiens DnaJ (Hsp40) homolog, subfamily B, member 9 
3 NM_015322.3 Homo sapiens fem-1 homolog b (C. elegans) (FEM1B) 
5 NM_005494.2 Homo sapiens DnaJ (Hsp40) homolog, subfamily B, member 6  
6 NM_006118.3 Homo sapiens HCLS1 associated protein X-1 (HAX1) 
11 NM_006118.3 Homo sapiens HCLS1 associated protein X-1 (HAX1) 
24 NM_002537.2 Homo sapiens ornithine decarboxylase antizyme 2 (OAZ2) 
25A NM_006118.3 Homo sapiens HCLS1 associated protein X-1 (HAX1) 
25B NM_000521.3 Homo sapiens hexosaminidase B (beta polypeptide) (HEXB) 
29A NM_001009186.1 Homo sapiens chaperonin containing TCP1, subunit 6A (zeta 1) 
29B NM_006118.3 Homo sapiens HCLS1 associated protein X-1 (HAX1) 
37 NM_006118.3 Homo sapiens HCLS1 associated protein X-1 (HAX1) 
43 NM_006145.1 Homo sapiens DnaJ (Hsp40) homolog, subfamily B, member 1 
45 NM_006118.3 Homo sapiens HCLS1 associated protein X-1 (HAX1) 
46 NM_006118.3 Homo sapiens HCLS1 associated protein X-1 (HAX1) 
49 NM_005494.2 Homo sapiens DnaJ (Hsp40) homolog, subfamily B, member 6  
52 NM_006118.3 Homo sapiens HCLS1 associated protein X-1 (HAX1) 
58 NM_006118.3 Homo sapiens HCLS1 associated protein X-1 (HAX1) 
63 NM_006118.3 Homo sapiens HCLS1 associated protein X-1 (HAX1) 
64 NM_006118.3 Homo sapiens HCLS1 associated protein X-1 (HAX1) 
68 NM_006118.3 Homo sapiens HCLS1 associated protein X-1 (HAX1) 
70 NM_006118.3 Homo sapiens HCLS1 associated protein X-1 (HAX1) 
71 NM_006118.3 Homo sapiens HCLS1 associated protein X-1 (HAX1) 
72 NM_006118.3 Homo sapiens HCLS1 associated protein X-1 (HAX1) 
73 NM_006118.3 Homo sapiens HCLS1 associated protein X-1 (HAX1) 
74 NM_006118.3 Homo sapiens HCLS1 associated protein X-1 (HAX1) 
82 NM_006118.3 Homo sapiens HCLS1 associated protein X-1 (HAX1) 
83 NM_006118.3 Homo sapiens HCLS1 associated protein X-1 (HAX1) 
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3.3 EspO1:Hax-1 interaction confirmed by direct Y2H 
 
To further confirm the interaction, the bait construct pGBKT7-EspO1 or pGBKT7-
EspO2 and the Gal4/AD vector, pGADT7 expressing HAX-1 were co-transformed in yeast 
strain AH109 (Figure 20). True positive interactions were assessed by the ability of co-
transformed AH109 to grow on high stringency media. To show that HAX-1 alone does not 
activate the reporters, AH109 containing the empty pGBKT7 vector with the pGADT7-Hax-
1 construct was also grown on high stringency media. Also to confirm that EspO1 or EspO2 
alone do not activate the reporters the pGBKT7 vectors expressing the effectors were co-
transformed with the empty pGADT7 vector. The transformed yeast strains were allowed to 
grow for five days and as shown in Figure 20, a clear difference in growth was observed on 
high stringency media between strains expressing both proteins and those expressing only 
one.  
 
Figure 20. Direct Y2H confirmation of EspO1 with Hax-1 
[I] pGBKT7-EspO1/pGADT7-HAX-1, [47] pGBKT7-EspO2/pGADT7-HAX-1, [III] 
pGBKT7-/pGADT7-HAX-1, [IV] pGBKT7-EspO1/pGADT7- , [V] pGBKT7-
EspO2/pGADT7-. 
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3.4 EspO1:Hax-1 interaction confirmed by Pull-Downs 
 
To further confirm the in-vitro EspO binding to Hax-1, the pMAL constructs (See 
Table 5) were used for an inducible expression and purification of EspO and then used for 
the pull-down assays. The pMAL system provides expression of the protein fused to MBP 
(maltose binding protein) and allows purification, which results from the binding of MBP to 
amylose. The expression profiles of EspO1 and EspO2 fused to MBP were sought in order 
to determine the solubility of the effector proteins and the optimum conditions required for 
increased yield. Growth at 30oC, 200 rpm until an OD of 0.5-0.6 was reached and then 
induction with 0.3 mM IPTG for 2 hours showed that both proteins are adequately 
expressed and remain soluble. The purified EHEC EspO1 and EspO2 fused to MBP were 
run on a 10% SDS-PAGE gel for validation (Figure 21).  
 
 
Figure 21. EspO purification 
The pMAL plasmids expressing EspO1 and EspO2 fused to MBP and empty pMAL vector 
expressing MBP fused to LacZ were used. Four samples were collected for each purified 
protein. The insoluble material and the unbound fraction (amylose column flow through) are 
also included (A-MBP:LacZ control, B-MBP:EspO1 and C-MBP:EspO2). The MBP:EspO1 
and MBP:EspO2 fusion proteins are 53 kDa. 
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For the pull-downs, we mixed amylose beads with whole HEK293 cell extracts with 
purified MBP-EspO1 or the negative control LacZ. The bound proteins were analysed by 
WB using MBP and Hax-1 antibodies, which showed that Hax-1 bound specifically to 
MBP-EspO1 but not to the negative control (Figure 22). 
 
Figure 22. In-vitro binding assay of EspO1:Hax-1 
Interaction of EspO1 (EHEC) with HAX-1 was confirmed with pull-down of endogenous 
HAX-1 from HEK293 cell lysates using Maltose Binding Protein (MBP):EspO fusions. 
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3.5 The EspO orthologs bind Hax-1 
 
Using the direct Y2H we investigated whether the other members of the EspO family 
of effectors also bound Hax-1. We found that similarly to EspO1, EspO2 of EHEC, EspO of 
the EHEC/EPEC-like mouse pathogen Citrobacter rodentium, OspE of Shigella and SopO 
of S. Typhimurium, also bound Hax-1 (Figure 23). Importantly, sequence alignment of the 
orthologs revealed that EspO shares 30 and 70% sequence identity with OspE and SopO of 
S. Typhimurium, respectively, while the SopO of S. Typhi (a human-restricted pathogen 
causing a systemic infection) is truncated, missing the C-terminal 18 amino acids (See 
Introduction, Figure 15.D). The direct Y2H assay revealed that SopO of S. Typhi did not 
bind Hax-1 (Figure 23).  
Consistently, deletion of the C-terminal 18 amino acids of EspO1 (EspO11-73), or 
addition of an HA tag to the C-terminus, abolished EspO:Hax-1 interaction (Figure 23), 
while the N-terminal 45 amino acids were dispensable (Figure 23). These results suggest 
that the C-terminus of EspO is essential for the interaction with Hax-1. As the interaction of 
the EspO orthologs with ILK is dependent on the conserved tryptophan (W68A in OspE and 
W77 in EspO), we tested the ability of EspO1W77A and OspEW68A to bind Hax-1. 
Importantly, using the direct Y2H assay we found that the conserved tryptophan residues 
play no role in the interaction between the EspO orthologs and Hax-1 (Figure 23). 
Additionally, we were  unable to confirm the interaction of EspO orthologs with ILK, using 
the direct Y2H assay. In conclusion, these results show that the EspO orthologs can also 
interact with other host cell partner proteins, which might confer insights to a novel EspO 
function. 
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Figure 23. EspO orthologs interact with Hax-1 
Hax-1 interacts with EspO orthologs from EHEC, C. rodentium, S. Typhimurium and S. 
flexneri. Mutation of the tryptophan residue (EspO1W77A or OspEW68A), previously shown to 
be important for the ILK interaction, does not affect binding to Hax-1, which interacts only 
with the N-terminal 45aa of EspO. The EspO homologue in S. typhi missing the C-terminal 
18 aa does not interact with either Hax-1.  
 
 
 
 
Figure 24. C-terminus of EspO1 required for Hax-1 interaction 
Deletion of the C-terminal 18 amino acids of EspO1 (EspO11-73) or addition of a C-terminal 
tag, abolished the EspO:Hax-1 interaction. 
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3.6 EspO interaction with DnaJ homolog subfamily B 
 
The Y2H screen also revealed members from the DnaJ homolog subfamily B. We 
further examined member 6 or DnaJB6 with direct Y2H. To further confirm the interaction, 
the bait construct pGBKT7-EspO1 or pGBKT7-EspO2 and the Gal4/AD vector, pGADT7 
expressing DnaJB6 were co-transformed in yeast strain AH109 (Figure 25). As previously 
described, true positive interactions were assessed by the ability of co-transformed AH109 
to grow on high stringency media. To show that DnaJB6 alone does not activate the 
reporters, AH109 containing the empty pGBKT7 vector with the pGADT7-DnaJB6 
construct was also included. As shown in Figure 25, a clear difference in growth was 
observed on high stringency media between strains expressing both proteins and those 
expressing only one.  
 
Figure 25. EspO interacts with DnaJB6 
Yeast can only grow on high stringency media when there is a true positive interaction 
between either EspO1 or EspO2 with DnaJB6. [I] pGBKT7-EspO1/pGADT7-DnaJB6, [47] 
pGBKT7-EspO2/pGADT7- DnaJB6, [III] pGBKT7-/pGADT7- DnaJB6, [IV] pGBKT7-
EspO1/pGADT7- , [V] pGBKT7-EspO2/pGADT7-. 
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 The DnaJ or Heat shock protein 40 (Hsp40) family is a major class of molecular co-
chaperones and its members are characterised by a highly conserved N-terminal amino acid 
sequence known as the ‘J-domain’ [220]. Although, distinct members are involved in a wide 
range of cellular processes, their main functions include protein folding and assembly of 
oligomeric complexes. Members of the human DnaJ family are classified in three 
subfamilies according to their conserved domains. Those included in subfamily A are 
closely related to the bacterial (E.coli) DnaJ and contain the N-terminal J-domain, a glycine 
or phenylalanine –rich domain and a cysteine-rich domain. Subfamily B members do not 
have the cysteine-rich domain and those in subfamily C lack both of these amino acid –rich 
regions but also their J-domain can be either N- or C- terminal. However, all of the DnaJ 
members require a functional J-domain, which is required to stimulate the ATPase-
functioning Hsp70 chaperoning machineries and hence, activate processes like protein 
refolding.  
Existing evidence suggests that members of the subfamilies A and B may act as 
chaperones independently of the Hsp70 machinery. Indeed, the EspO protein partner 
DnaJB6 or human homolog MRJ has been shown to suppress toxic protein aggregation 
[220]. Additionally, it is involved in other cellular processes like cell adhesion and motility 
through an interaction with the urokinase plasminogen activator surface receptor (uPAR or 
PLAUR) [221], the regulation of keratin turnover through interaction with keratin 
intermediate filaments (K8/K18) [222] and the regulation of cell cycle due to its up-
regulation in the M-phase of mammalian cell cycle but also due to its nuclear translocation 
during interphase [223]. Furthermore, DnaJB6 / MRJ has been suggested to have a role in 
cancer due to an interaction with a metastasis suppressor protein, BRMS 1 [224]. 
 96 
Using the direct Y2H we found that similarly to Hax-1, DnaJB6 also interacts with 
EspO1, EspO2 of EHEC, EspO of the EHEC/EPEC-like mouse pathogen Citrobacter 
rodentium, OspE of Shigella and SopO of S. Typhimurium but not with SopO of S. Typhi, 
which lacks the C-terminal 18 amino acids (Figure 26). Consistently, DnaJB6 also binds 
only the C-terminal 45 amino acids of EspO1 (Figure 26). These results suggest that the C-
terminus of EspO is essential for both the interaction with Hax-1 and DnaJB6. The direct 
Y2H assay also revealed that the conserved tryptophan residues (W68A in OspE and W77 
in EspO), which were previously shown to be important for the ILK binding, play no role in 
the interaction between the EspO orthologs and DnaJB6 (Figure 26). In total the Y2H 
results show that, similar to many other T3SS effectors, the EspO orthologs can interact 
with multiple host cell partner proteins. 
 
Figure 26. EspO orthologs bind DnaJB6 
The interaction pattern of DnaJB6 is identical to Hax-1 and shows positive interaction with 
the EspO orthologs from EHEC (EspO1 and EspO2), C. rodentium (EspO), S. Typhimurium 
(SopO) and S. flexneri (OspE). Mutation of the tryptophan residue (EspO1W77A or 
OspEW68A), previously shown to be important for the ILK interaction, does not affect 
binding to DnaJB6, which interacts only with the N-terminal 45aa of EspO. The EspO 
homologue in S. typhi missing the C-terminal 18 aa does not interact with either Hax-1 or 
DnaJB6.  
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4 Chapter 4 : Intracellular Localisation  
 
4.1 Protein Structure Prediction 
 
To gain further insights in the localisation and function of EspO, we analysed the 
prediction of the protein structure using bioinformatic softwares available online. The three-
dimensional (3D) protein structure of EspO1 from EHEC, SopO from S. Typhimurium and 
OspE from S. flexneri were predicted by I-TASSER (http://zhanglab.ccmb.med.umich.edu 
/I-TASSER/). This is an online platform that accepts the amino acid sequence of the target 
protein and returns the model of the 3D structure based on sequence alignments or 
homology between the target protein and a representative set of all known structures and 
further retrieves information by scanning templates from other libraries including enzyme 
classification, gene ontology and ligand-binding sites [225, 226]. The models were analysed 
with the Chimera package (http://www.cgl.ucsf.edu/chimera) to present images of the 
ribbon and the resulting surface of each structure (Figure 27.A).  
The N-terminal region of EspO1 contains a small alpha helix (position 5-6) and a 
second alpha helix is predicted between the 72nd and 86th amino acid (Figure 27.B). 
Interestingly, the tryptophan at position 77 (W77) previously shown to be important for the 
ILK binding lies within the alpha helix. As previously shown in this study, the direct Y2H 
experiments confirmed that the C-terminal 18 amino acids of EspO1 are also required for 
the interaction with both Hax-1 and DnaJB6. EspO1 and SopO share many structural 
properties due to their high levels of homology. As previously mentioned, the two orthologs 
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share 70% amino acid identity. Both sequences contain long amino acid chains, which are 
found within beta strands.  
 
A. Models of 3D structures 
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B. Secondary structure prediction 
 
Figure 27. Models of EspO1, SopO and OspE 
A. The 3D structures of EspO1 (EHEC), SopO (S. Typhimurium) and OspE (S. flexneri) 
modelled by I-TASSER and analysed with the Chimera package to show the ribbon from N-
terminus (Blue) to C-terminus (Red) and the resulting surface of each predicted ribbon 
structure. B. The amino acid residues for each protein with the prediction of the secondary 
structure (coil-C, helix-H and strand-S) and the level of confidence shown on a scale of 0-
10. 
 
	   Similarly to EspO1, the N-terminal region of SopO, contains 3 amino acids that are 
found within an alpha helix and the C-terminal region is mainly comprised of an alpha helix 
with 14 amino acids (from 72 to 86). In contrast, the secondary structure prediction for 
OspE does not have the N-terminal alpha helix that exists in both EspO1 and SopO models 
(Figure 27.B). However, the protein folding modelled by I-TASSER predicts highly similar 
final models for the 3D structures of EspO1, SopO and OspE.  
Additionally, the predicted structures were matched with structures of known biological 
function and localisation with TM-align, a software included in the I-TASSER platform for 
structural alignment. The ranking of the best matches is based on a scale from 0 to 1. EspO1 
shows structural similarities with ferredoxin oxidoreductases (e.g. PDB 2x9oA with 
alignment score 0.527) and phosphatases (e.g. PDB 3fxoA1 with score 0.508). The 
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consnesus gene ontology (GO) terms predicted for EspO1 includes an oxidoreductase 
process for biological function (GO:0055114) with mitochondrial localisation 
(GO:0005739).  
SopO shows structural similarities with nucleoporins (e.g. PDB 3ikoC with score 
0.528), methyl coenzyme-M reductases (e.g. PDB 1hbuD with score 0.524) and 
bacteriophytochromes (e.g. PDB 4ehoA with score 0.502). The consesus GO terms for 
SopO describe the enzymatic release of energy from organic compounds (GO:0009061) 
with a nuclear membrane localisation (GO:0005643). Interestingly, OspE shows structural 
similarities with another Salmonella SPI-2 T3SS effector, PipB2 (PDB 2lezA with score 
0.519) that binds kinesin light chain and it is involved in Sif formation and additionally 
localises on vesicles [227-229]. OspE also shares similarities with a yeast protein Ndc10 
(PDB 3t79A with score 0.513), which is involved in mitosis.  
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4.2 Transfection of EspO in HeLa cells 
 
To examine the sub-cellular localisation of EspO, HeLa cells were transfected with 
mammalian vectors expressing either espO1 or espO2 from EHEC, espO from C. 
rodentium, sopO from S. Typhimurium and ospE from S. flexneri all with an N-terminal 
myc tag. Ectopically expressed GFP was used as a control. Immunofluorescence staining of 
myc-EspO showed that intracellular EspO appears at the surface of a large vacuole (Figure 
28). Moreover, transfection of EspO in HeLa cells induces reorganisation of the 
mitochondria labelled with Mitotracker compared to the GFP transfected cells. 
Mitochondria are pulled closer together forming a concentrated cluster surrounded by EspO 
(Figure 28). In contrast, OspE, the EspO ortholog from Shigella, appears as smaller tubular 
vacuoles, which co-localise with the mitochondria without any effect on their organisation.  
In order to confirm the reorganisation observed with MitoTracker, the mitochondria 
were also labelled with the specific antibody anti Cytochrome C oxidase IV (COX IV), 
which is one of the enzymes localised to the inner mitochondrial membrane. In the presence 
of EspO1 (EHEC) or SopO (S. Typhimurium), the mitochondria show no reorganisation 
when compared to the untransfected control (Figure 29). However, the Shigella homologue 
OspE shows co-localisation with the mitochondria similarly to MitoTracker labelling 
(Figure 29). In the case of EspO1 the staining with COX-IV confirms that MitoTracker is a 
false positive whereas OspE shows co-localisation in both stainings confirming a possible 
role related to the mitochondria. As previously mentioned, the bioinformatic analysis of the 
3D structures and motifs included in the EspO orthologs predicts an ability to act as 
bacterial electron carriers. This might further explain the false positive result observed with 
MitoTracker, which is a probe that enters the cell in its reduced form and becomes 
fluorescent when oxidised. 
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Figure 28. Intracellular localization of EspO (A) 
Localisation of EspO1 and EspO2 (EHEC) or EspO (C. rodentium) in transfected HeLa 
cells appears at the surface of a large vacuole, which reorganises and further colocalises 
with mitochondria labelled with MitoTracker. In contrast, OspE only co-localises with the 
mitochondria. The effectors were detected with an anti-myc antibody (Green) and 
mitochondria were stained with MitoTracker Red CMXRos (red). A negative control pRK5 
expressing GFP is also shown in the figure. 
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Figure 29. Intracellular Localisation of EspO (B) 
The specific mitochondrial antibody COX-IV (Green) shows no co-localisation or re-
organisation of the mitochondria in HeLa cells transfected with EspO1 (EHEC) or SopO (S. 
Typhimurium) and detected with anti-myc antibody (Red). Whereas OspE (S. flexneri), also 
stained with anti-myc antibody (Red) co-localises with the mitochondria.  
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To further characterise the composition of the EspO vacuole, specific markers of 
various cellular compartments were used. No co-localisation was observed with the early 
endosomes (Rab5), late endosomes (Rab7) or Golgi apparatus (GM130). In co-transfections 
of EspO1 with the endoplasmic reticulum (ER) marker CREB3, we observed re-
organisation of the ER compared to the CREB3 only transfected cells (Figure 30). However, 
this result remains inconclusive due to lack of reproducibility with other ER specifc 
markers. The ER network labelled with the ER-GFP (CellLight, Invitrogen) remains 
unaffected in EspO1 transfections and the vacuole appears to reside above the ER network 
(Figure 31).  
  
  
Figure 30. Intracellular Localisation of EspO (C) 
The EspO vacuole stained with anti-myc antibody (Blue) re-organises the ER network 
stained with the ER specific marker CREB3 and labelled with anti-HA antibody (Green). 
The ER network is re-organised in the EspO1-CREB3 co-transfected cells compared to the 
CREB3 only tranfected cells. Scale bars indicate 5 µm.  
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Figure 31. Intracellular Localisation of EspO (D) 
Endoplasmic reticulum (ER) network stained with the CellLight ER-GFP, Invitrogen 
(Green) is not re-organised in pRK5-EspO1 HeLa cell transfections. The EspO vacuole 
stained with anti-myc antibody (Red) appears to reside above the ER network. Scale bars 
indicate 5 µm.   
  
We also investigated whether the EspO phenotypes seen when transiently expressed 
with the mammalian vector pRK5 and tagged with an N-terminal myc epitope, are 
confirmed in a different construct background. For this, we transfected HeLa cells with 
pCDNA3.1 expressing Flag tagged EspO1. Although, the main phenotypes observed were 
the same as the pRK5 background, we additionally observed in 10% of the transfected cells 
a combined phenotype of vacuole formation and focal adhesion localisation (Figure 32). 
This might be a case of difference in expression levels between the two constructs allowing 
the formation of smaller vacuoles and hence, other minor phenotypes can be detected by 
immunofluorescence, which are otherwise masked by the large and brighter vacuolar 
concentration of EspO. 
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Figure 32. EspO1 localised at focal adhesions and vacuoles 
Ectopic expression of EspO1 (EHEC) using N-terminal Flag tag localises on the surface of 
vacuoles and focal adhesion sites. EspO1 was detected with an anti flag antibody (Red) and 
DAPI was used to detect nuclei (Blue). Arrows show focal adhesion site localisation and 
star shows vacuoles.  
 
 
In conclusion, the EspO vacuoles seen in transfected HeLa cells might be localised 
only within the cytoplasm. However, more experimental work is required to confirm our 
current understanding regarding the intracellular localisation.  
 
 
 
 
 
 
 107 
4.3 EspO1 localisation in EHEC / EPEC infections  
 
In order to localize EspO during infection, we generated a double EHEC espO1/espO2 
mutant. The mutant was complemented with an IPTG inducible plasmid encoding C-
terminal HA-tagged EspO and the IPTG concentration was optimised to balance the 
inducible expression of espO with the effects on growth rate. We infected mouse illeal 
epithelium in an ex-vivo model and using scanning electron microscopy (SEM), we 
investigated whether the absence of espO affects the A/E lesion formation and cellular 
exfoliation. There was no difference in either A/E formation or cellular exfoliation between 
EHEC EDL933 and double espO mutant (Figure 33).  
 
 
Figure 33. Scanning Electron Micrograph of EHEC infections 
Deletion of espO in EHEC does not affect the A/E lesion formation compared to the EHEC 
EDL933 wild type strain. Arrows show pedestal formation. 
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Kim et al. [130] have shown that OspE localises at the sites of focal adhesion where it 
binds ILK to increase adherence of infected cells. Immunofluorescence staining showed that 
similarly to OspE, the tagged EspO1 localized at FA during EHEC infections (Figure 34). 
However, the direct Y2H showed that the C-terminus of EspO1 is important for Hax-1 
binding (See Chapter 3), which means that the C-terminal tag interferes with this interaction. 
Additionally, the N-terminus of EspO1 contains the translocation signal, meaning that we 
were also unable to insert an N-terminal tag. Therefore, we could not determine any further 
information related to the localisation of EspO attributed to the Hax-1 interaction during 
infections.  
 
 
Figure 34. EspO1 localised at FA in EHEC infections 
C-terminal HA-tagged EspO1 is localised at focal adhesion sites in the complemented 
double EspO EDL933 mutant. EspO1 was detected with an anti-HA antibody (Red), Actin 
with Phalloidin Green and an anti-O157 antibody (Blue) for EHEC bacteria. Scale bars 
indicate 5 µm. 
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4.4 EspO1 co-localises with Hax-1   
 
Ectopic expression was used to study the intracellular localisation of EspO without 
interfering with the Hax-1 interaction. To investigate whether EspO affects the localisation 
of Hax-1 we transfected HeLa cells with eukaryotic expression vectors encoding N-terminal 
myc-tagged EspO1 and detected with an anti myc antibody. Endogenous levels of Hax-1 
were detected with an anti Hax-1 antibody using immunofluorescence microscopy. This 
reveealed that endogenous Hax-1 appears to co-localize with EspO1 at the vacuoles. In 
untransfected HeLa cells endogenous Hax-1 is dispersed in the cytosol, which is reorganised 
into a vacuole in EspO transfected cells (Figure 35). Additionally, Hax-1 appears to 
translocate into the nucleus in EspO transfected cells. These results are consistent with the 
reported nuclear localization of endogenously and ectopically expressed Hax-1 in HeLa 
cells [201, 230].  
 
Figure 35. EspO1 co-localises with endogenous Hax-1 
Endogenous Hax-1 is re-organised and co-localises with the large vacuole formed in 
ectopically expressed myc tagged EspO. EspO1 was detected with an anti myc antibody 
(Green) and endogenous Hax-1 was detected with anti Hax-1 antibody (Red). Scale bars 
indicate 5 µm in main images and scale bars for ROIs show 2.5 µm. 
 110 
 
To confirm the visual estimate of colocalisation shown in Figure 35, we used a 
statistical approach to analyse the images and quantify co-localisation as a coincidence of 
intensity distributions. This approach is based on intensity correlation coefficients, which 
were calculated with ImageJ / Fiji, a freely-available online open source software package 
for image processing (http://fiji.sc/Fiji). The Pearson’s coefficient (PC) was calculated to 
provide a quantitative indication of the linear relationship between the grey values of the 
two channels or images (Figure 36). The values from the two images were plotted against 
each other and displayed on a scatter plot which shows complete co-localisation between the 
two images (Figure 37). This is determined by the relationship of the pixel values from each 
channel, which is represented by the distribution of the dot cloud along the fitted line. PC 
provides this distribution and gives a measure of the quality of the relationship or correlation 
between the two channels. The PC values range from -1 to 1 where -1 means negative 
correlation, 0 indicates no correlation and 1 for complete positive correlation.  
 
Figure 36. Analysed images 
The two channels from the co-localistion experiment were used to perform statistical 
analysis of the correlation of grey value pixel intensity. The merged dual-channel image in 
Fig. 36 was split into the individual channels and the two resulting images were used for the 
statistical analysis done with ImageJ. 
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Figure 37. Scatter Plot 
The pixel grey values from the images in Fig.37 are plotted against each other on a scatter 
plot (A) or fluorogram (B) where the x-coordinate shows the intensity of Cy3 (Hax-1) pixels 
and the y-coordinate represents the intensity of the corresponding Cy2 (EspO1) pixels. The 
relationship between the intensities of the two images is calculated by linear regression and 
shown by the fitted line on the plot. The graphs show a complete colocalisation, which is 
represented by a concentration of the dot cloud along the line. ImageJ was used for the 
analysis. 
 
 
The PC value is 0.948, which indicates complete co-localisation. The slope of the 
line is shifted towards the x-axis, which indicates a difference in the intensities between the 
two channels with Cy3 being more intense. However, this difference is minimal and does 
not affect the co-localisation that is still observed but indicates the existence of a small 
subpopulation of red pixels which has appeared due to a less sensitivity in the green 
channel. It should be noted that this is different from channel cross-talk or bleed-through, 
which is represented by a complete shift of the line towards one of the axis on the scatter 
plot [231].  
To confirm co-localisation, the Manders’ overlap coefficient (MC) was calculated for 
each image. This ranges from 0 to 1 with 1 being an indication of 100% co-localisation and 
0 indicating no overlap between images. MC defines the proportion of each channel that is 
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co-localised with the other and for this calculation a threshold is required to exclude any 
background noise that might exist in each image [232]. The two MC values generated are 
0.95 for the fraction of the Cy3 image (Hax-1) overalapping Cy2 image (EspO1) and 0.973 
for the opposite fraction (i.e. Cy2 overlapping Cy3). 
A statistical confidence of the co-localisation is given by the Costes’ approach which 
is based on image randomisation and further evaluation of PC calculated from thresholded 
images [233]. The statistical approach compares the PC values from the original non-
randomised images with those calculated from the randomised images and a P-value or 
significance is calculated (given as a percentage). For this, we used 1000 randomisation 
rounds (200 rounds are proposed to give a significant statistical distribution) to ensure 
reliable elimination of false positives. The PC is 0.941 and has a P-value of 100% meaning 
that co-localisation is highly probable.  
Additionally, we measured co-localisation according to a cross-correlation function 
that discriminates between the different co-localisation events by shifting the Hax-1 image 
pixel per pixel across the x-axis and relative to the EspO1 image [234]. The respective PC is 
calculated and then plotted as a pixel shift function (δx). A peak at 0 pixel shift (x-value) 
indicates a complete colocalisation event between the two images as it is shown for EspO1 
and Hax-1 (Figure 38). The intensity correlation analysis using Li’s correlation coefficient 
was performed as a last approach to interpret co-localisation on separate graphs for each 
image that represent normalised intensities (0-1 on y-axis) as a function of the covariance 
(i.e. relationship between the two variables) of both channels’ intensities (x-axis) [235]. If 
there is co-localisation the pixel cloud has only positive x values and therefore situated on 
the right side of x=0 line as shown for the EspO1 and Hax-1 images (Figure 39).  
In conclusion, the statistical analysis performed with different approaches confirms 
that the visual estimate of co-localisation observed in Figure 35, is a true positive co-
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localisation of EspO1 and Hax-1. However, this is the result taken from one co-localisation 
experiment and therefore, requires reproducibility. 
 
 
 
Figure 38. Cross-correlation analysis 
Cross-correlation functions (CCF) were determined using a pixel shift of δ=±20. Graph 
shows complete co-localisation of the EspO1 and Hax-1 images, which is represented by a 
curve with maximum peak at δ=0. ImageJ was used for the analysis. 
 
 
Figure 39. Intensity correlation analysis 
Intensity correlation analysis indicates co-localisation between EspO1 and Hax-1. A graph 
for each channel representing intensity distribution in the channel (y-axis) is plotted against 
the covariance of both channels (x-axis). Pixels with positive x-values (situated on the right 
of the x=0 line) show co-localisation. ImageJ was used for the analysis. 
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5 Chapter 5 : EspO role in Apoptosis and Inflammation   
 
5.1 Inhibition of apoptosis induced by various stimuli 
 
Hax-1 is a potent inhibitor of apoptosis and executes this activity by preventing XIAP 
degradation and inactivating SERCA2 (hence diminishing ER Ca2+ content and protecting 
the mitochondria from Ca2+ overload). Therefore, we investigated the role of the EspO 
orthologs in apoptosis. We challenged EspO ortholog-transfected HeLa cells with 
staurosporine (STS), which is a pro-apoptotic agent that inhibits protein kinases. We 
quantified the number of transfected cells with active caspase-3 (main executioner of 
apoptosis) and fragmented DNA (late apoptotic feature) by immunofluorescence.  
Untransfected or transfected with the gfp control STS-treated cells displayed high 
levels of cleaved caspase-3 and fragmented DNA (70-80%), whereas significantly (P<0.05) 
lower levels (10-20%) were observed in cells transfected with the EspO orthologs (Figure 
40). The positive control cells transfected with the already known anti-apoptotic EHEC 
effector NleH showed low levels (18%) of cleaved caspase-3 similar to the EspO orthologs 
(Figure 40.A). To determine whether binding to ILK is involved in this anti-apoptotic 
function, we tested the activity of EspO1W77A and OspEW68A. Ectopic expression of the 
mutant effectors was as effective as the wild type proteins in inhibiting STS-induced 
apoptosis (10-20%) (Figure 40.A). Importantly, the level of apoptosis in cells ectopically 
expressing the S. Typhi SopO, which cannot interact with Hax-1, was examined by the 
TUNEL assay and revealed 60-70% apopoptotic nuclei similar to the apoptotic levels shown 
by negative control cells (70-80%) (Figure 40.B).  
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To ensure that the effectors on their own do not induce apoptosis, we transfected 
HeLa cells without the addition of pro-apoptotic agents. The uninduced EspO ortholog 
transfected cells show similar levels of cleaved caspase-3 (Figure 41.A) and condensed 
nuclei (Figure 41.B) to the uninduced gfp control, which is significantly lower than the STS-
treated gfp control. 
 
A. EspO inhibition of STS induced apoptosis assessed by cleaved Caspase-3 
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B. EspO inhibition of STS induced apoptosis assessed by TUNEL 
 
 
 
 
 
Figure 40. Inhibition of Staurosporine induced apoptosis 
EspO orthologs protect against staurosporine (sts) induced apoptosis in HeLa cells as 
measured by cleaved Caspase-3 staining (A) and apoptotic nuclei assessed by TUNEL (B). 
The levels of cleaved Caspase-3 (A) and apoptotic nuclei (B) were significantly reduced in 
cells transfected with the NleH positive control and the EspO orthologs (10-20%) compared 
to the untransfected or transfected with the gfp control STS-treated cells (70-80%). The 
level of apoptosis in cells transfected with the S. Typhi SopO showed increased levels of 
apoptotic nuclei (60%) (B). Three biological replicates with two technical replicates each 
(100 transfected cells counted per technical replicate) were analysed for statistical 
significance with the two-tailed unpaired t-test with equal SD. *P<0.05. 
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A. Levels of cleaved Caspase-3 in STS treated and untreated EspO transfected HeLa cells 
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B. Levels of condensed nuclei in STS treated and untreated EspO transfected HeLa cells 
 
 
Figure 41. STS treated and untreated EspO transfected cells 
Uninduced EspO ortholog transfected cells are non-apoptotic with similar low levels (5-
10%) of cleaved caspase-3 (A) and condensed nuclei (B) compared to the gfp control cells 
without treatment (0-5%). The level of apoptosis is significantly higher in gfp control cells 
induced with staurosporine (70-80%) compared to the untreated control cells (0-5%). Three 
biological replicates with two technical replicates each (100 transfected cells counted per 
technical replicate) were analysed for statistical significance with the two-tailed unpaired t-
test with equal SD. *P<0.05. 
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To investigate the ability of EspO orthologs to inhibit apoptosis triggered by other 
stimuli, we challenged EspO transfected cells with tunicamycin (TUN), which disrupts the 
function of the ER leading to unfolded protein responses and thapsigargin (TG), an inducer 
of apoptosis through specific inhibition of the Ca2+ ATPase SERCA2 pump. Quantification 
of transfected cells by immunofluoresence revealed that tunicamycin-treated HeLa cells 
transfected with either EspO1 or EspO1W77A showed low levels (10-20%) of cleaved 
caspase-3, similar to the NleH positive control (10-20%) and untreated gfp control (0-5%) 
((Figure 42.A).  
Furthermore, we found low levels of apoptosis (20-30%) in thapsigargin treated cells 
transfected with EspO1, SopO and OspE compared to the untransfected control (80-90%) 
(Figure 42.B). The uninduced EspO ortholog transfected cells show similar levels (0-5%) of 
cleaved caspase-3 (Figure 43.A) and condensed nuclei (Figure 43.B) to the uninduced gfp 
control (0-5%), which is significantly lower than the TUN-treated gfp control (70-80%). 
Taken together these results show that EspO orthologs, irrespective of the ILK binding, 
interfere with numerous cellular pathways leading to inhibition of apoptosis triggered by 
various inducers.  
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A. EspO inhibition of TUN induced apoptosis assessed by cleaved Caspase-3 
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B. EspO inhibition of TG induced apoptosis assessed by TUNEL 
 
 
 
 
 
Figure 42. Inhibition of apoptosis induced by ER stress 
EspO orthologs protect against tunicamycin (tun) induced apoptosis in HeLa cells as 
measured by cleaved caspase-3 staining (A) and thapsigargin (tg) induced apoptosis 
measured by apoptotic nuclei assessed by TUNEL (B). The levels of cleaved Caspase-3 (A) 
and apoptotic nuclei (B) were significantly reduced in cells transfected with the NleH 
positive control and the EspO orthologs (10-20%) compared to the untransfected or 
transfected with the gfp control treated cells (70-80%). Three biological replicates with two 
technical replicates each (100 transfected cells counted per technical replicate) were 
analysed for statistical significance with the two-tailed unpaired t-test with equal SD. 
*P<0.05. 
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A. Levels of cleaved Caspase-3 in TUN treated and untreated EspO transfected HeLa cells 
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B. Levels of condensed nuclei in TUN treated and untreated EspO transfected HeLa cells 
 
 
 
Figure 43. TUN treated and untreated EspO transfected cells 
Untreated EspO ortholog transfected cells are non-apoptotic with similar low levels (5-10%) 
of cleaved caspase-3 (A) and condensed nuclei (B) compared to the gfp control cells without 
treatment (0-5%). The level of apoptosis is significantly higher in gfp control cells induced 
with staurosporine (70-80%) compared to the untreated control cells (0-5%). Three 
biological replicates with two technical replicates each (100 transfected cells counted per 
technical replicate) were analysed for statistical significance with the two-tailed unpaired t-
test with equal SD. *P<0.05. 
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5.2 EspO1 inhibits apoptosis during infections 
 
Work in the Frankel group has previously reported that infection of HeLa cells with 
EPEC and EHEC nleH mutants leads to apoptosis and cell detachment that could be 
prevented by pre-treatment with the global caspase inhibitor, Z-Vad-fmk [48]. To 
investigate if EspO can substitute for Z-Vad-fmk, we transformed EPEC E2348/69 (which 
is naturally espO negative) ΔnleH with plasmids encoding untagged (to allow EspO:Hax-1 
interaction) full length EspO1 or EspO1W77A.  
HeLa cells were seeded 48 hours prior to infection at a density of 5x104 to have 80-
90% cell confluency in 24-well plates on the day of infection. The lower level of adherent 
cells remaining in plates infected with EPEC E2348/69 ΔnleH1 ΔnleH2 was obvious under 
the microscope (10-20%) when compared to the EPEC E69 wild-type (80%) and the double 
nleH mutant expressing either full-length EspO1 or W77A EspO1 (80%). For every 
condition, the remaining adherent cells were examined by immunofluorescence for 
membrane blebbing indicated by cell shrinkage and rounding and apoptotic stress in 
mitochondria labelled with anti Cytochrome – c. Cell detachment, membrane blebbing or 
changes in the mitochondrial network were not obvious in the wild-type or the double nleH 
mutant expressing either full-length EspO1 or W77A EspO1 meaning that EspO1 was able 
to inhibit the apoptosis induced by the nleH-mutant (Figure 44). Taken together these results 
show that the EspO orthologs are potent inhibitors of apoptosis in HeLa cells and execute 
this function in an ILK-independent manner.   
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Figure 44. An ILK-independent EspO inhibition of apoptosis in EPEC infections 
EspO1 or EspO1W77A complemented EPEC E2348/69 double nleH mutant inhibit membrane 
blebbing and cell detachment induced by the nleH-mutant. 50 adherent cells were examined 
by immunofluorescence for each condition. Actin was stained with Phalloidin Green, 
mitochondria labelled with anti – Cytochrome – c (Red) and an anti-O127 antibody (Blue) 
for EPEC bacteria. 
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5.3 EspO inhibition of apoptosis is Hax-1 dependent 
 
To investigate whether Hax-1 is directly involved in the anti apoptotic activity of the 
EspO orthologs, we treated HeLa cells with Hax-1 siRNA and induced apoptosis with STS. 
Silenced Hax-1 expression was confirmed by Western blotting (Figure 45). Hax-1 depleted 
and untransfected cells did not trigger apoptosis without STS treatment. HeLa cells depleted 
of Hax-1 were then transfected with EspO1, SopO or OspE, treated with STS and assessed 
by TUNEL. The EspO ortholog-transfected cells showed high levels of apoptosis (60-80%) 
similar to the control untransfected cells (Figure 45). Taken together, these results show that 
EspO orthologs protect cells from apoptosis in a Hax-1 dependent manner.  
Furthermore, we investigated whether Hax-1 is also directly involved in the EspO 
ability to inhibit the apoptosis, induced specifically by ER stress. As previously described, 
we treated HeLa cells with siRNA and silenced Hax-1 expression was confirmed by 
Western blotting (Figure 46). In this case, we induced apoptosis using the ER-stress inducer, 
TUN. Hax-1 depleted and untransfected cells did not trigger apoptosis without STS 
treatment. HeLa cells depleted of Hax-1 were then transfected with EspO1, SopO or OspE, 
treated with STS and assessed by TUNEL. The EspO ortholog-transfected cells showed 
high levels of apoptosis (60-80%) similar to the control untransfected cells (Figure 46). 
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Figure 45. Hax-1 dependent EspO inhibition of apoptosis 
EspO orthologs cannot protect against staurosporine induced apoptosis in Hax-1 depleted 
HeLa cells. Apoptotic nuclei assessed by TUNEL. The level of apoptosis is significantly 
higher in untransfected control cells and EspO ortholog transfected cells induced with 
Staurosporine (60-70%) compared to the untreated control cells (5-10%). Three biological 
replicates with two technical replicates each (100 transfected cells counted per technical 
replicate) were analysed for statistical significance with the two-tailed unpaired t-test with 
equal SD. *P<0.05. 
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Figure 46. EspO inhibition of ER stress is Hax-1 dependent 
EspO orthologs cannot protect against tunicamycin induced apoptosis in Hax-1 depleted 
HeLa cells. Apoptotic nuclei assessed by TUNEL. The level of apoptosis is significantly 
higher in untransfected control cells and EspO ortholog transfected cells induced with 
Tunicamycin (70-90%) compared to the untreated control cells (10%). One biological 
replicate with two technical replicates (50 transfected cells counted per technical replicate) 
are shown. 
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5.4 Preliminary in-vivo study of EspO : Histopathology 
 
In order to investigate the role of EspO in the in-vivo pathogenesis of C. rodentium 
(CR), we generated an espO deletion mutant. As mentioned earlier, this is a commonly used 
model of EPEC or EHEC infection in mice but there are certain limitations. Although, the 
EHEC EspO effectors were previously confirmed as T3SS effectors, Deng et al. have shown 
in an in-vitro study on C. rodentium T3SS effectors that CR EspO might not be secreted by 
the type III secretion system [213, 236]. However, the homology shared between EHEC and 
CR EspO but also the common behaviour shared in the in-vitro experimental work 
discussed in previous chapters, induced us to examine the role of EspO in a physiological 
setting.  
We orally infected C57BL/6 mice with wild-type CR (ICC169), the espO mutant 
and the mutant complemented with full-length EspO or EspOW77A (to abolish the EspO:ILK 
interaction) and monitored CR by enumerating the number of colony forming units per gram 
of stools (cfu g-1) collected at regular intervals following inoculation. All strains were 
peaked at day 8 and although at different rates, all strains started to clear from day 11 post-
inoculation. Differences were observed in the rate of clearance for espO deletion mutant, 
which appears to be more persistent in comparison to the EspO complemented strain or wt 
CR (Figure 47). To ensure the in-vivo plasmid stability in the complemented strain we 
performed differential antibiotic plating and showed that the plasmid was fully stable over 
the course of the infection (Figure 48).   
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Figure 47. Colonisation rates of C. rodentium infection in-vivo 
C. rodentium wt strain showing similar colonisation with EspO mutant and complemented 
strains up to day 11. Clearance rates are similar between the wt and complemented strains 
but the EspO mutant appears more persistent. Full clearance is seen at day 19 post-
inoculation for all strains. Graph shows the mean value from 8 mice per condition. Courtesy 
of Dr V. Crepin-Sevenou. 
 
 
Figure 48. Plasmid complementation stability in-vivo 
The stability of the plasmids used for complementation was confirmed by differential 
antibiotic plating during the course of infection. Stool samples taken during the course of 
infection were plated with antibiotics to ensure the presence of the transformed plasmid. 
Differential antibiotic plating was used to select for both the espO mutation (kanamycin) 
and the complementation plasmid (chlorampenicol). Courtesy of Dr V. Crepin-Sevenou. 
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Light microscopy analysis of colonic sections from mice infected with the espO 
mutant showed a statistically significant reduction in hyperplasia levels (measured by length 
of crypt per condition) compared to the wild type and complemented strains (Figure 49). 
Colonic mucosal hyperplasia is the hallmark of CR infection and is characterized by 
elongation of the colonic crypts, goblet cell depletion, mucosal erosion, increased mitotic 
activity or cell proliferation and increased infiltration of immune cells. The decreased levels 
observed with the espO mutant were similar to the uninfected control. We additionally 
tested the mutant strain complemented with EspO(W77A) to abolish the ILK interaction and 
this showed similar levels to the wild type and EspO complemented strain (Personal 
communication with Dr V. Crepin-Sevenou). Furthermore, we examined the tissue sections 
for protein expression by Western blot analysis, which revealed that Hax-1 is signigicantly 
up-regulated in C. rodentium infection (Figure 49.C). Therefore, ILK remains independent, 
which suggests that an EspO:Hax-1 interaction might be regulating crypt epithelial 
proliferation and apoptosis to promote the hyperplastic phenotype in CR in-vivo model of 
EHEC/EPEC infection.  
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A. Hyperplasia Graph 
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B. H & E staining of tissue sections 
 
 
 
C. Hax-1 expression levels 
 
 
Figure 49. Histopathology of EspO in-vivo 
A. Hyperplasia as measured by crypt length from H &E staining of tissue sections is 
reduced in the EspO mutant compared to the wild type and the complemented mutant strain. 
Data is shown as mean +/- SD. B. H & E staining of tissue sections used to measure colonic 
hyperplasia. C. Western blot analysis showing increased Hax-1 expression levels in 
C.rodentium (CR) infected mice compared to the uninfected control reveals a possible role 
of Hax-1 in CR infections. Courtesy of Dr V. Crepin-Sevenou. 
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5.5 EspO regulates inflammation in-vivo 
 
Hyperplasia is the hallmark of CR infections and this is presented partly by mucosal 
inflammation. Therefore, we investigated whether the ability to recruit immune cells to the 
site of bacterial infection could be, at least to a certain extend, attributed to EspO. We 
employed fluorescence microscopy to examine neutrophil and CD4+T cell recruitment on 
colonic cryosections. Ly6G surface antigen and CD4 (respectively) positive cells were 
detected following infection with CR wild type, espO mutant and complemented with EspO. 
Both neutrophil and CD4+-T cell recruitment was higher in colonic sections from mice 
infected with the EspO complemented mutant whereas espO deletion mutant shows 
marginally reduced levels compared to wild-type CR (Figure 50). These data suggest that 
EspO plays a direct role in recruiting neutrophils and CD4+-T cells to the site of bacterial 
infection. In addition, the decreased levels of inflammatory cell infiltration could further 
explain the reduction of hyperplasia observed following mice infected with espO deletion 
mutant.  
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A. Neutrophil Counts 
 
 
B. CD4+T cell Counts 
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C. Neutrophil Ly6G staining of frozen sections  
 
 
Figure 50. Neutrophil and CD4+T cell Counts 
A. The EspO mutant strain shows lower levels of neutrophil infiltration compared to the 
wild type and EspO complemented mutant strain. B. CD4+T cell infiltration is less in mice 
infected with the mutant compared to the wild type and EspO complemented strain. 
Neutrophils and CD4+T cells counts presented as a mean of counts from two tissue sections 
from four different mice per condition. C. Increased neutrophil infiltration in wild type and 
EspO complemented strain compared to the uninfected control or mutant strain are shown 
by Ly6G stainings of frozen sections. Immunofluorescent stainings were kindly performed 
by Dr V. Crepin-Sevenou. 
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6 Chapter 6 : Discussion 
 
In this work, we present a T3SS effector paradigm illustrating an orchestrated 
influence of multiple signalling pathways leading to cell survival. As previously reported, 
the EspO orthologs interact with ILK at FA sites to stabilise host cell attachment on the 
extracellular matrix [130]. Our results show that EspO orthologs also interact with Hax-1 to 
additionally protect host cells from apoptosis and regulate inflammation. We propose a 
novel EspO mechanism that might be employed by enteric bacteria and involves the 
protection of Hax-1 from degradation, which is normally executed by caspase-3 and 
Omi/HtrA2 [199, 206]. Potentially this enables EspO orthologs to regulate a key anti 
apoptotic Hax-1 interactome, which may include the potent inhibitor of apoptosis XIAP 
[197]. Figure 51 illustrates a suggested model for the T3SS EspO orthologs within the 
context of an infection with enteric bacteria. 
Microbial intrusion of the intestinal environment is sensed by pattern recognition 
receptors (PRRs) mainly bound at the cell surface but can also localise in the cytosol or even 
internalised in vesicles [237]. The PRR families associated with bacterial recognition 
include the well-characterised Toll-like receptors (TLRs) and the nucleotide binding 
oligomerisation domain (NOD)-like receptors (NLRs) [238, 239]. In a heathly intestine, 
TLRs and NLRs interact with the naturally available ligands often provided by the 
commensal microbiota. Their action maintains the intestinal epithelial barrier by regulating 
signalling pathways involved in cell survival [240]. The TLR- and NLR- specific ligands are 
known as pathogen associate molecular patterns or PAMPs and include lipopolysaccharides, 
peptidoglycan (e.g. muramyl dipeptide – MDP), flagellin and nucleic acids. PAMPs enable 
the pathogen to manipulate the first line of host defence and evade the intestinal barrier 
[241].    
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Figure 51. Illustrating a novel EspO model (Designed by author) 
In a hypothetical model, EspO orthologs from EPEC / EHEC, Shigella and Salmonella may 
interact with Hax-1 to regulate the onset of apoptosis but also the inflammatory response 
initiated by the NOD signalling, upon bacterial recognition. Illustration was designed by the 
author for this study.  
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MDPs in epithelial cells are endocytosed in a clathrin-dependent internalisation 
within vesicles, which communicate with members of the NLR signalling [242]. 
Interestingly, the two main players of the NLR family, known as NOD1 and NOD2, are 
homologues of the apoptotic protease-activating factor (APAF1) and also regulate 
inflammation through NF-κB [239]. Once stimulated, they form multimeric complexes by 
recruiting protein kinases (RIP2, TAK1:TAB1 complex, TAB2 and the most essential 
IKKα-IKKβ-NEMO complex for NF-κB activation), ubiquitin recruiters (TNF receptor 
associated factors TRAF6 and TRAF2) and the inhibitors of apoptosis XIAP and cIAP. An 
intriguing study by Krieg et al. showed that XIAP interacts with the receptor-interacting 
protein kinase 2 (RIP2) to regulate downstream NOD signalling [243]. Recently, Damgaard 
et al. demonstrated that RIP2 ubiquitination is a XIAP-dependent E3 ubiquitin ligase action 
that recruits LUBAC, another important member of the ubiquitination system to regulate the 
NOD2 only signalling cascade [244]. When XIAP is absent, the NOD2 signalling is not 
facilitated and this results in decreased production of NF-κB targets (e.g. IL-8) [244].  
The ubiquitination system in eukaryotic cells is a key mechanism used to separate 
proteins required to maintain their function (e.g. Lys-63 or M1) from those assigned for 
elimination (Lys-48 or U-48 in Fig. 5) by the 26S proteasome [245, 246]. Both XIAP and 
the LUBAC complex promote linear M1-linked ubiquitination in NOD2-RIP2 signalling 
[244]. The process of ubiquititnation attracts enteric bacteria and T3SS effectors like NleG 
from EHEC / EPEC, IpaH from Shigella or SopA, SlrP and SspH from Salmonella have 
been shown to function as E3 ubiquitin ligases [247-251]. Additionally, the SPI-2 T3SS 
deubiquitinase SseL counteracts the ubiquitin ligase-functioning effectors in Salmonella 
[114]. In this study, we showed that EspO orthologs exhibit an anti-apoptotic activity that 
depends on Hax-1. Once Hax-1 is protected from degradation, the formation of a binding 
complex with XIAP might be promoted.  
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The Hax-1:XIAP interaction was shown to suppress XIAP polyubiquitination and 
thus, protect it from being degraded by the ubiquitin / proteasome system [197]. Regulation 
of XIAP is fascilitated by HtrA2/Omi and Smac/Diablo, which are mitochondrial proteases 
released in the cytosol upon induction of apoptosis [176]. XIAP consists of 3 baculovirus 
IAP repeats (BIRs) which are commonly found in IAPs to confer the anti-apoptotic ability, 
one ubiquitin binding domain (UBA) and a C-terminal RING domain which functions as an 
E3 ubiquitin ligase [252]. The N-terminal BIR domain 1 is required for TAK1:TAB1 
complex that allows XIAP to regulate NF-κB activation whereas BIRs 2 and 3 are involved 
in the inhibition of caspases -3, -7 and -9. HtrA2/Omi and Smac/Diablo interact with BIRs 2 
and 3, which can be additionally occupied by Hax-1 [197]. The latter prevents the 
interaction of pro-apoptotic proteases with XIAP and therefore, promotes its intracellular 
stability. Additionally, the RING domain functions as an auto-survival mechanism, which 
ubiquitinates proteases like Smac/Diablo [253].  
In this study, we also show a co-localisation of EspO and Hax-1 with cytosolic 
vacuoles, which might be a result of a XIAP-dependent recruitment of the Hax-1:EspO 
complex to the MDP-containing vesicles that stimulate NOD2 signalling. However, since 
our observation is restricted to ectopically expressed EspO and endogenous Hax-1, the 
vacuole formation might also be a Hax-1 participation in clathrin-mediated endocytosis due 
to its integrin β6-binding site [254]. The vacuoles formed in EspO transfected cells also co-
localise with the ER marker CREB3 (a transcription factor residing at the ER and once 
activated, it travels to the nucleus to enhance cell proliferation). Consistently, multiple viral 
proteins also target Hax-1 to interfere with apoptotic pathways and both ER and nuclear 
redistribution of Hax-1 was reported [209, 211, 212]. We further confirm a nuclear 
localisation of both ectopically expressed EspO1 and endogenous Hax-1. The consensus 
HeLa cell localization of Hax-1 includes mitochondria, ER and nuclear membrane [255].  
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Once enteric bacteria evade the first line of defence, they work towards establishing 
an infection by utilising their T3SS effector repertoire. In a C. rodentium model the T3SS 
effector NleE was shown to alter colonization and disease severity when absent [256]. In 
addition, the EHEC / EPEC T3SS NleB along with NleE and its Shigella homologue OspZ 
are able to block NF-κB activation and nuclear translocation of the p65 subunit [50]. In 
EPEC infections, the action of NleE and NleB affect interleukin-8 (IL-8) secretion and this 
allows transepithelial migration of neutrophils from the submucosa to the lumen [257]. 
Shigella was shown to use this neutrophil migration as a port of entry towards the 
basolateral membrane [258, 259]. Furthermore, the Shigella effectors IpaH9.8, OspB and 
OspF but also SspH1, the IpaH9.8 homologue in Salmonella are targeted to the nucleus to 
supress the production of IL-8 [111-113].  
Bacteria also block NF-κB activation by targeting the NOD signalling and depletion 
of NOD2 worsens S. Typhimurium and L. monocytogenes infections [260-262]. The 
intracellular action of EspO orthologs might also promote bacterial survival through an 
interaction with Hax-1, which in turn binds XIAP to prevent its degradation. However, 
whether the RING domain of XIAP, which is essential for NOD2 signalling, is still 
functional within the Hax-1:EspO conformational complex would require further 
investigation. Possibly by testing the M1-specific ubiquitination of XIAP in the presence of 
EspO orthologs. A non-functional RING domain in XIAP is known to cause X-linked 
lymphoproliferative disease (XLP) and mainly affects the immune system [263, 264]. 
Additionally, non-functional NOD2 has been identified as a cause of the prolonged bacterial 
infection in inflammatory bowel diseases like ulcerative colitis or Crohn’s [241, 265, 266]. 
The latter is a disease characterised by diminished neutrophil and T cell function caused by 
pro-inflammatory cytokines, like the potent neutrophil chemoattractant IL-8, which are 
being severely affected by defects in NF-κB activation [267]. Importantly, a non-functional 
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Hax-1 has been identified as an important genetic marker for severe congenital neutropenia 
or Kostmann disease, which describes an immunodeficiency syndrome with increased 
apoptosis in neutrophils [268]. 
Once infected however, the intestinal environment is forced to battle for survival. 
This involves cellular communication governed by Ca2+, a key ionic messenger that 
coordinates cellular development and activity but also triggers their death [185]. Whether a 
cell is irreversibly committed to suicide is also dependent upon a homeostatic crosstalk 
governed by Ca2+ signalling [185]. Attenuated homeostasis allows Ca2+ to orchestrate 
apoptosis, which is considerably regulated by the interaction of Hax-1 with the active ER-
specific Ca2+ importer, SERCA2 [193, 205]. Cells over expressing Hax-1 exhibit down 
regulation of SERCA2 and this presents an inhibition of apoptosis through diminished ER 
Ca2+ content. 
Apart from SERCA2, Hax-1 participation in Ca2+ homeostasis may also include its 
interaction with the ER localised polycystic kidney disease type II, PKD2 or TRPP2 [201]. 
In a dimeric complex, PKD1 and PKD2 form cationic channels that permit a two-way 
direction Ca2+ flux [202]. The PKD2 channels were shown to inhibit apoptosis by permitting 
less ER Ca2+ export to the cytosol and mitochondria in association with the ER Ca2+ efflux 
channels, inositol triphosphate receptors (IP3Rs) [203, 204]. In EHEC / EPEC infection the 
action of IP3Rs is also targeted by the T3SS NleH, which inhibits apoptosis through a direct 
interaction with Bax inhibitor-1 (BI-1). Interestingly, specific C-terminal conformational 
changes additionally localise PKD2 at the nucleus to activate transcription factors regulating 
genes involved in cell proliferation [269, 270].  
In addition, silencing of PKD2 in a human colonic epithelial cell line results in 
decreased activation of NF-κB and IL-8 production [271]. Non-functional pkd1 and pkd2 
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genes cause autosomal dominant polycystic kidney disease (ADPKD), which is 
characterised by enlarged kidneys due to increased proliferation and apoptosis [272]. 
Additionally, the lcn2 expressed human neutrophil lipocalin (NGAL) or oncogene 24p3 is a 
potent genetic marker for ADPKD [273, 274]. Neutrophils release NGAL at sites of 
infection to bind bacterial ferric siderophores [275, 276]. The complexes are then 
endocytosed within cytosolic vesicles, which subsequently release the siderophores to 
activate iron-dependent inflammatory pathways. Intriguingly, NGAL is now considered as a 
potent biomarker for renal failure in children suffering from HUS commonly caused by 
Shiga toxin-producing EHEC infections [277-279].  
The preliminary in-vivo data shown in this study, indicate a significant role of EspO 
in the regulation of inflammatory responses mediated by IL-8 and presented by an increase 
in both neutrophil and CD4+ T cell infiltration in mice infected with wild type C. rodentium 
and the complemented strains but not in the espO mutant. Therefore, EspO orthologues 
might be able to control IL-8 production through their interaction with Hax-1, which 
maintains a stable intracellular XIAP. This in turn, might lead to an inhibition of apoptosis 
but also a control of host cell inflammation through the NF-κB regulation of IL-8.  
Although, there is an abundance of elements suggesting an important EspO 
contribution in bacterial survival within the infected host, it is still speculative to say that it 
is included in the auxiliary T3SS effector proteins that worsen the outcome of infection. 
Whether the in-vitro EspO:Hax-1 interaction has a physiological meaning is currently being 
further investigated with the C. rodentium model employed for in-vivo studies of EHEC / 
EPEC infection. Our current understanding introduces a T3SS effector commonly expressed 
in enteric bacteria to promote their infective life inside the host and its presence within the 
effector repertoire might be a determinant of disease severity in certain pathogenic strains.  
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